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Isolation of Bioactive Components from Ecuadorian 
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Chapter 1. Introduction 
 
 
1.1 About Aristolochia 
Aristolochia is an important genus in the family of Aristolochiaceae. The genus 
Aristolochia consists of about 400 species of herbaceous perennials, undershrubs or shrubs 
bearing essential oils and is widespread across tropical Asia, Africa and South America.1 Various 
species of Aristolochia have been used as medicaments and tonics (Table 1).2 In China, with the 
name “Madouling”, the mature fruits of A. debilis are still used for the treatment of snakebite, 
tuberculosis and as antihypertensive agents.3 Some species have been used in the form of crude 
drugs as anodynes, antiphlogistics and detoxicants. 
 
 
1.2 Ethnopharmacology 
In last two decades, phytochemical and pharmacological studies on Aristolochia have been 
carried out and a variety of compounds has been isolated. Among them, aristolochic acid 
derivatives and terpenoids are widespread in almost all of these plant species.  
In 1991, the first description of the Belgian epidemic of Chinese herbs nephropathy during a 
slimming regimen,4 which was caused by the consumption of herbal remedies containing 
aristolochic acid (extracted from A. fangchi), a devastating renal disease affecting men and 
women living in rural areas of Bosnia, Bulgaria, Croatia, Romania, and Serbia was found. This 
disease is a rapidly progressive interstitial fibrosing nephropathy frequently associated with 
urothelial cancer.5 After that, pharmacological action of the genus Aristolochia has been 
intensely researched, and found to possess immunostimulatory and anti-inflammatory6 as well as 
nephrotoxic,7 carcinogenic8 and mutagenic activities.9 The biological activities of the members 
of Aristolochia were summarized in Table 2.10
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Table 1 Traditional/folklore medicinal uses of Aristolochia species 
 
Botanical name Trivial name Part used Popular use 
A. acutifolia Jiquiro, Jarrinha Whole plant Treatment of erysipelas 
A. albida  Rhizomes Ointment for skin diseases; treatment of dysentery, 
  gastrointestinal colics and snakebites; as an adjuvant 
A. argentina Charrua, Charruga Aerial parts As an emmenagogue, antiseptic, diaphoretic and 
  diuretic; treatment of arthritis, poisoning, and pruritus 
A. baetica  Roots As emmenagogue; anticancer 
A. birostris Capivara, Angilico Roots anticancer 
Jarrinha   
A. bracteata Ukulwe, Bracteated Whole plant As an emmenagogue, anthelmintic, purgative, mosquito 
birthwort  repellent, antidote, anodyne and insecticide 
A. brevipes Guaco Rhizomes Treatment of arthritis, wounds, snakebites and toothache 
A. chamissonis   Whole plant In debility 
A. chilensis Oreja de zorro, Hierba Roots  Treatment of abundant lochia (puerperal secretions); as 
de la virgin Maria  an emmenagogue 
A. cinnabarina Sichuan zhusalian Roots  As an analgesic and pain killer  
A. clematitis Upright birthwort Roots Treatment of cancer, menstrual troubles, legulcers, 
  wounds and tumors; as a depurative and insect repellent 
A. contorta  Pipevine,Ma dou ling, Roots  anticancer  
Tian xian teng   
A. constricta  Saragez Aerial parts  As an antispasmodic, analgesic, anticancer, antimalarial 
  and antiinflammatory agent; as an emmenagogue; 
  treatment of snakebites 
A. cucurbitifolia  Qing muxiang  Fruits, roots As an anodyne, antiphlogistic, expectorant, antitussive 
  and antiasthmatic agent; treatment of snakebites and 
  lung inflammation 
A. debilis  Ma dou ling, Qing Roots  As a bronchiectatic; to decrease high blood pressure  
muxiang, Seimokkou,   
Birthwort long, Chinese   
fairly vine, Birthwort   
A. gibertii  Mil hombres hembra, Whole plant Treatment of swelling; in stomach pain; as an ailment  
Contrayerba, Patito   
A. gigantea   Whole plant As an emmenagogue, abortive and antiseptic; treatment 
  of wounds and skin diseases 
A. grandiflora   Aerial parts  As a uterotonic, cytotoxic and antimicrobial agent; 
  treatment of snakebites; as a fly and maggot repellent 
A. heterophylla Yellowmouth, Fruits, roots As an expectorant, antitussive, antiasthmatic and 
Dutchman’s pipe  analgesic; treatment of snakebites 
A. indica Indian birthwort Roots As an emmenagogue, cardiotonic, diuretic, 
  antiinflammatory, abortifacient and mild sedative; 
  against intestinal worms, poisonous bites and stings 
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Botanical name Trivial name Part used Popular use 
A. kaempferi Yellowmouth, Whole plant Treatment of asthma, coughs and piles; as an antivenom,
Dutchman’s pipe  antibacterial agent, antipruritic, hypotensive, 
  expectorant, and emetic 
A. kankauensis  Fruits, roots As an expectorant, antitussive, analgesic and 
  antiasthmatic 
A. liukiuensis   Roots As an antiphlogistic, detoxicant and anodyne  
A. longa  Tian xian teng Whole plant  Treatment of cancer, sclerosis, uterus tumors and nose 
  cancers 
A. macroura Mil hombres, Patito Whole plant Treatment of snakebites and rheumatism; as a circulatory
Coludo, Jarrinha,  stimulant, antiinflammatory, antiseptic and abortive 
Isipomilhombres   
A. manshuriensis Manchurian birthwort, Whole plant As a bronchiectatic; to decrease high blood pressure  
Manchurian Duchman’s   
pipe, Guan mu tong,   
Kan-mokutsu,   
Mokuboi, Kwangbanggi   
A. maurorum Zarand Roots As an antiseptic; in wound healing; for scab of sheep  
A. mollissima Xun gu feng Fruits, roots As an analgesic, anticancer, antimalarial, 
  antiinflammatory, antirheumatic and bronchiectatic 
  agent; to decrease high blood pressure; treatment of 
  stomach ache and abdominal pain 
A. paucinervis Barraztam Whole plant Treatment of skin infections, gas gangrene, abdominal 
  pain and infections of the upper respiratory tract 
A. rotunda  Whole plant In cancer; as a depurative 
A. rodriguesii  Sangue-de-Cristo  Roots,  As an abortifacient and antiinflammatory; treatment of 
 aerial parts snakebites 
A. triangularis  Mil hombres  Bark As an antirheumatic, antifertility agent, diaphoretic, 
  diuretic, antiseptic, emmenagogue, antidote, and 
  abortive; treatment of wounds and skin diseases 
A. tuberosa   Roots Treatment of sore throats, venomous snakebites, and 
  tuberculosis 
A. yunnanensis  Yunnan ma dou ling, Roots  Treatment of gastrointestinal diseases, trichomoniasis, 
Nan mu xiang  and various pains 
A. zollingeriana  Madouling Fruits, roots As an expectorant, painkiller, antitussive, antiasthmatic, 
  and analgesic; treatment of snakebites 
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Table 2 Ethnopharmacological data of Aristolochia species 
 
Botanical name  Plant material  Bioactivity 
A. albida  Rhizomes Antifeedant Insecticidal Antispasmodic  
A. argentina Aerial parts Insecticidal, antibacterial, antifungal 
A. bracteata  Seeds  Toxicity to goat, Antiinflammatory, antibacterial, analgesic 
A. bracteolate  Whole plant Antiplasmodial 
A. constricta Whole plant Antispasmodic 
A. debilis  Whole plant  
Inhibition of COX-2 activity, inhibition of iNOS activity,  Inhibit
testosterone reductase, Inhibition of lipid peroxide formation, Inhib
of melanin formation 
A. elegans  Whole plant   Antimitotic, Antiviral 
A. fructus  Whole plant Leukotriene B4 receptor antagonist activity  
A. grandiflora Whole plant Neutralizing ability against the haemorrhagic effect  
A. indica  Aerial parts Antibacterial  
 Roots  
Tumor inhibitory, Abortifacient activity, Interceptive activity 
Antispermatogenic effect 
A. macroura  Leaves  Cytotoxicity 
A. manshuriensis  Cell suspension Cardiotonic, antihypoxic activity  
 Culture Synergistic effect for pesticides  
 Whole Plant Inhibition of mutagenicity of Trp-P-1  
A. mollissima  Whole plant  Antirheumatic, arthritis treatment, Contraceptive 
A. aff. orbicularis  Roots Repellent effect against the corn borer Sitophilus zeamais 
A. papillaris Whole plant Smooth muscle relaxant activity 
A. paucinervis  Rhizomes, leaves  
Antibacterial, Bacteriostatic, bactericidal, Anti-Helicobacter pyrol
activity, Antidermatophytic, antifungal 
A. taliscana  Roots  Trypanocidal 
A. triangularis  Whole plant  
Cytotoxicity, inhibition of growth of crown gall tumors Typical 
c-mitotic action 
A. trilobata  Leaves, bark  Antibacterial, Antiphlogistic, antiinflammatory 
 
 
 
 
 
 
 
 
 
 
 
 
1.3 Biosynthesis of main components in Aristolochia. 
1.3.1 Biosynthesis of aristolochic acid 
 
    Aristolochic acid occurs in various species of the genus Aristolochia and several other 
members of the family Aristolochiaceae.  
    Spenser et al. reported a biosynthesis of aristolochic acids.11 A number of 14C-labelled 
compounds was administered to intact plants by infusion into the stem through a cotton wick, 
and in each case radioactive aristolochic acid-I was then isolated from roots and rhizomes in A. 
sipho. The results indicated a postulated route: norlaudanosoline → orientaline → orientalinone 
→ orientalinol → stephanine → aristolochic acid-I, which involves a phenol coupling step and a 
dienol-benzene rearrangement (Figure 1). 
    Feeding of (L)-[U-14C]tyrosine to A. bracteata has been studied by Kapil.12 The evidence 
strongly supports the hypothesis that the oxidative coupling of orientaline gives prestephanine, 
which is converted into stephanine leading to aristolochic acid by oxidative cleavage.  
 
 
Figure 1. Proposed biosynthesis of aristolochic acid-I 
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1.3.2 Biosynthesis of diterpenes, kaurene and kaurenoic acid. 
    Diterpenoids constitute a large group of compounds derived from geranylgeranyl 
pyrophosphate (GGPP). ent-Kaurane type diterpenes were widely isolated from Aristolochia 
genus and formed from GGPP via ent-copalyl pyrophosphate (CPP) (Figure 2). The pathway of 
ent-kaurene biosynthesis was first confirmed using cell-free systems from Gibberella fujikuroi.13 
Copalyl diphosphate synthase (CPS) and ent-kaurene synthase (KS) were thought to be involved 
in the two-step cyclization. Oxidation of ent-kaurene by a cytochrome P450 enzyme would lead 
to the formation of ent-kaurenoic acid.14
 
 
Figrue 2. Pathway for ent-kaurene and kaurenoic acid biosynthesis. 
 
 
1.3.3 Biosynthesis of lignan 
    Lignan is a class of dimeric phenylpropanoids widely spreaded in the genus Aristolochia, 
which showed remarkable biological properties, e.g. antitumor, antimitotic, and antiviral 
properties. 
Recently, hinokinin biosynthesis in Linum corymbulosum Reichenb. was reported and two 
hypothetical pathways were outlined for the biosynthesis of (-)-hinokinin (Figure 3).15 In both 
pathways, (+)-pinoresinol serves as the primary substrate. In the first pathway, pinoresinol is 
reduced via lariciresinol to secoisolariciresinol by a pinoresinol-lariciresinol reductase (PLR), 
and methylenedioxy bridges are formed later. In the second pathway, pinoresinol itself is a 
substrate for formation of the methylenedioxy bridges, resulting in consecutive production of 
piperitol and sesamin. One pinoresinol-lariciresinol reductase (PLR-Lc1) was isolated and found 
to be enantiospecific for the conversion of (+)-pinoresinol to (-)-secoisolariciresinol.15 This 
results support the first pathway. 
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Figure 3. Hypothetical biosynthetic pathways to (-)-hinokinin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 8
 1.4 About Aristolochia constricta 
 
A. constricta Griseb, known as the common name Saragosa (or Saragez), is widely 
distributed in south America. The aerial parts of this plant have been empirically used in folk 
medicine as antispasmodic, anticancer, antimalarial, and anti-inflammatory agents, an 
emmenagogue, and as a treatment for snake bites.16  
To our knowledge, only limited reports on the chemical constituents of A. constricta have 
appeared in the literatures.  Five new protopine-type alkaloids, 3,5-di-O-methylconstrictosine 
(1), 5,6-dihydro-3,5-di-O-methylconstrictosine (2), 5,6-dihydroconstrictosine (3), constrictosine 
(4), and 3-O-methylconstrictosine (5), and a novel 8-benzylberberine-type alkaloid, 
(-)-8β-(4’-hydroxybenzyl)-2,3-dimethoxyberbin-10-ol (6) were isolated from the aerial parts, 
among which constrictosines 1-5 significantly reduced electrically-induced (ECI), 
acetylcholine-induced (AChI), and histamine-induced contractions in isolated guinea-pig 
ileum.17 These new protoine alkaloids from A. constricta induced a significant reduction of 
morphine withdrawal in vitro, too.18  
 
 
 
Their continuing search for new bioactive metabolites led to the isolation of aristolochic 
acids I (7) and IV (8) and four new aristolactam glycosides (9-12), together with sinapoic acid 
and β-hydroxy-3’,4’-dimethoxy phenylethyl glucoside. 17 
 
R1
R2
R3
N
O
O
OH OH
OH
R4O
R1 R2 R3 R4
9 OCH3 OCH3 H H
10 OCH3 OCH3 H
11 OCH3 OCH3 OCH3 H
12 OH OH OH H
O
OH
O
O
COOH
NO2
OCH3R
Aristolochic acid I (7) R=H
Aristolochic acid IV (8) R=OCH3  
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1.5 Previous study in our laboratory 
In 2004, Mochizuki started to isolate the bioactive components from the Ecuadorian A. 
constricta in our laboratory,18 the aerial parts (6.63 g) were successively extracted using Soxhlet 
apparatus with n-Hexane, CHCl3 and EtOH (Chart 1). Each extract was tested on the ECI and 
AChI contractions of guinea-pig ileum (Table 3).  
 
extracted by Soxhlet apparatus 
Aristolochic acid I 
washed with n-Hexane 
washed with ether 
(-)-Cubebin 
washed with ether  
and n-Hexane 
column chromatography (C.C.) 
Benzene: AcOEt=1:2 
washed with ether  
and n-Hexane 
A. constricta (whole part)（6.63 g）
n-Hexane ext. 
334.3 mg 
CHCl3 ext. 
272.3 mg 
EtOH ext. 
654.1 mg 
fil.(311.9 mg) ppt.(2.6 mg) 
Fr.4 
fil. ppt. 
fil. ppt. 
fil. ppt. (35 mg) 
Chart 1. Systematic separation of extracts of A. constricta by Mochizuki. 
Table 3. Effects of the hexane, CHCl3, and EtOH extracts on ECI and AChI contractions in isolated guinea-pig 
ileum. 
Dose  
(mg/mL) 
Contraction of ileum by  
electric impulse (%) 
Contraction of ileum 
 by acetylcholine (%) 
n-Hexane ext. 0.03 
0.01 
67.2 
14.7 
89.3 
2.9 
CHCl3 ext. 0.03 
0.01 
45.4 
7.2 
72.9 
1.4 
EtOH ext. 0.03 
0.01 
31.4 
12.9 
101.6 
59.3 
   
However, her results concerning the relaxant effects differed from those of Rastrelli et al,17 
and she found that the hexane and CHCl3 extracts significantly inhibited ECI and AChI 
contractions in isolated guinea-pig ileum. Therefore, she studied on the n-Hexane and CHCl3 
 10
extracts, to isolate (-)-cubebin (13), and aristolochic acid I (7) respectively. 
According to Mochizuki’s method, Shimokawa scaled up the separation of A. constricta 
(412.9 g) (Chart 2), and focused on the components of the CHCl3 extract.19 
 
extracted by Soxhlet apparatus 
washed by Et2O 
ppt. 
1). washed with n-Hexane
2). repeated C.C. 
fil. 
a part (6.9819 g) 
washed by n-Hexane 
A. constricta（412.9g）
n-Hexane ext. 
8.4344g (2.04%) 
CHCl3 ext. 
7.8318g (1.90%) EtOH ext. 
61.01 g (14.8%) 
Fr. A 
2.7073g Fr.B 
2.4425g
Fr.C 
1.5636g
Compounds 13-18 
residue 
Chart 2. Systematic separation of extracts of A. constricta by Shimokawa. 
As a result, six known components were isolated from Fr. B after washing with n-Hexane 
and column chromatography (C.C.): (-)-cubebin (13), (-)-hinokinin (14), 
(+)-4,7-dimethyl-6-methoxy-1-tetralone (15), (-)-kauran-16α,17-diol (16), (-)-kaur-16-en-19-oic 
acid (17), and (-)-kaur-15-en-17-ol (18). 
(-)-Cubebin (13)
O
O
O
O
O
OH
(-)-Hinokinin (14)
O
O
O
O
O
O
OH
OH
H
H
(-)-Kaurane-16a, 17-diol (16)
H3C CH3
H
H
(-)-Kaur-16-en-19-oic acid (17)
H3C COOH
H3C
H
H
(-)-Kaur-15-en-17-ol (18)
H3C CH3
H3C OHH3C
H3CO
H3C
O
HH3C
(+)-4,7-Dimethyl-6-methoxy-1-tetralone (15)
 
Figure 4. Isolated compounds from the Ecuadorian A. constricta by Shimokawa. 
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Based on the previous works, author decided to continue Shimokawa’s work of isolating 
bioactive components from the Ecuadorian A. constricta, and to study pharmacological effects 
on the ECI and AChI contractions of isolated guinea-pig ileum. 
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Chapter 2. Isolation 
 
2.1 Antispasmodic effects of each extract 
The stem parts of A. constricta, collected at Mocache, LosRios province, in the coastal 
region of Ecuador, were successively extracted using Soxhlet apparatus with hexane, CHCl3, and 
EtOH. Each extract was subjected to antispasmodic tests on an isolated guinea-pig ileum. The 
hexane and CHCl3 extracts (0.03–0.1 mg/mL) potently inhibited ECI and AChI contractions in a 
concentration-dependent manner, as shown in Table 4. On the other hand, the EtOH extract 
showed only a weak inhibitory effect on ECI and AChI contractions. On the basis of these results, 
it was speculated that antispasmodic constituents were present mainly in the hexane and CHCl3 
extracts.   
 
Table 4.  Effects of the hexane, CHCl3, and EtOH extracts on ECI and AChI contractions in isolated 
guinea-pig ileum. 
Extract Concentration (mg/mL) ECI Contraction (%) AChI Contraction (%) 
Hexane 0.03 47.1 ± 5.4 b 45.4 ± 13.0 a
 0.1 5.7 ± 1.5 b 10.9 ± 4.6 b
CHCl3 0.03 52.1 ± 10.4 b 37.8 ± 13.5 a
 0.1 9.5 ± 3.6 b 2.9 ± 0.6 b
EtOH 0.03 77.8 ± 8.14 94.4 ± 5.5 
 0.1 49.7 ± 7.0 b 64.6 ± 8.7 a
Contraction (%) is expressed as a percentage against control contraction induced by electrical stimulation or 
ACh in the absence of samples.  Each value shows mean ± S.E.M of four to five animals.  a P < 0.05, b P < 
0.01, significantly different from control contraction (%) (paired t-test)  
 
 
 
    From the soluble part (Fr. A) of the CHCl3 extract, compound A-I was isolated by repeated 
C.C. Insoluble part of the CHCl3 extract against n-hexane was further washed with Et2O to 
separate into soluble (Fr. B) and insoluble (Fr. C) parts. Compounds A-II～A-VI were isolated 
from the former, and A-VII from the latter. Compounds A-VIII and A-IX were isolated from the 
EtOH extract by repeated C.C. (Chart 3). 
 
 
 
 
 
 extracted by Soxhlet apparatus 
 repeated C.C. 
ppt. fil. 
repeated C.C. 
 repeated C.C.
washed by Et2O 
ppt. 
1). washed with n-Hexane
2). repeated C.C. 
fil. 
a part (6.9819 g) 
washed by n-Hexane 
A. constricta（412.9g）
n-Hexane ext. 
8.4344g (2.04%) 
CHCl3 ext. 
7.8318g (1.90%) EtOH ext. 
61.01 g (14.8%) 
Fr. A 
2.7073g 
Fr.B 
2.4425g
Fr.C 
1.5636g
Compounds A-II～A-VI 
Chart 3. Systematic separation of extracts of A. constricta. 
Compounds A-I 
Compounds A-VIII～A-IX 
Compound A-VII 
 
 
 
 
2.2 Structure Elucidation of isolated compounds 
2.2.1 Structure Elucidation of compound A-I 
A new compound A-I was isolated as a colorless gum. The EIMS spectrum showed a 
molecular ion [M+] at m/z 626, which was consistent with the molecular formula C40H50O6, and 
two characteristic fragment peaks at m/z 355 (24%) and m/z 288 (9%), which implied that this 
compound was derived from cubebin [C20H20O6 (356.37)] (13) and kaur-15-en-17-ol [C20H32O 
(288.47)] (18) units, respectively (Table 5).  
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Figure 5.   Structure of compound A-I       Figure 6. Selected of HMBC correlations of A-I 
 
Table 5. EIMS data (%) of A-I, 13, and 18. 
 
 
The 1H (Table 6) and 13C (Table 7) NMR spectra of A-I showed a reasonable combination 
of these units through dehydration, even the appearance of complex signals due to the presence 
of a diastereomeric mixture of cubebin (13) (Figure 5). Correlations of these carbons and protons 
could be deduced by DEPT, HMQC, and HMBC experiments. Especially, connection of the 
cubebin and kaurene units through an ether bridge was established by HMBC correlations 
between the 17-hydrogens [δH 3.97 and 4.13 (for A-I a) and δH 3.85 and 4.19 (for A-I b)] and the 
9'-carbon [δc 107.0 (for A-I a) and δc 104.1 (for A-I b)] and between the 9'-hydrogen [δH 4.83 
(for A-I a) and δH 4.81 (for A-I b)] and the 17-carbon [δc 64.4 (for A-I a) and δc 65.2 (for A-I 
b)] (Figure 6). Comparison of the 1H NMR spectrum of A-I with those of 13 and 18 allowed us 
to deduce a combination of 13 and 18 (Figure 7). Thus, a new diterpeno-lignan hybrid A-I was 
determined to be an inseparable diastereomeric mixture of 9-O-[(-)-kaur-15-en-17-oxyl]cubebin.   
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 OH
H
H
H3C CH3
O
O
O
O
O
OH
(-)-Kaur-15-en-17-ol (18)
(-)-Cubebin (13)
A-I 
 
Figure 7．1H NMR spectra of compounds 13, 18 and A-I 
 
Cubebin (13) have three chiral centers on a lactol ring, including epimerizable hemiacetal 
carbon. Lopes et al.20 recently isolated (-)-cis- and (-)-trans-cubebin as a single and a part of 
inseparable diastereomeric isomers at the C9′ hemiacetal carbon, respectively, and precisely 
analyzed their stereochemistry using NMR data. Based on their discussion, it was concluded that 
(-)-cubebin (13a, b) isolated by us was a 3:2 diastereomeric mixture of the trans derivatives. 
Relative stereochemistry (C8’ and C8’’) of compound A-I (trans or cis), was accessed by 
comparison of NMR data of A-I with the reported 1H and 13C NMR data of trans-cubebin (13a, 
b) (Tables 6 and 7) indicating that compound A-I was a 1:1 diastereomeric mixture of the trans 
derivatives. 
To establish the above conclusion, we treated a diastereoisomeric mixture of (-)-cubebin (13) 
with (-)-kaur-15-en-17-ol (18) in dichloromethane in the presence of 0.1 M camphorsulfonic acid 
(CSA) at room temperature for 3 days and then reflux for 2 days in which an identical acetal 19 
to the new hybrid A-I was given, although in low yield (2.4%) (Scheme 1).  
    Scheme 1. Synthesis of acetal 19 from (-)-cubebin (13) and (-)-kaur-15-en-17-ol (18). 
 
Aristolochic acid esters connected to (-)-kauran-16α,17-diol are known to be hybrid 
components of A. pubescens,21 however, to our knowledge, this is the first case of the isolation of 
a unique diterpeno-lignan hybrid from the same species.  
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Table 6. The 1H NMR (600 MHz, CDCl3) spectral data of A-I, 13, and 18. 
 
 A-I a A-I b 13a 13b 18 
position δH (J in Hz) δH (J in Hz) δH (J in Hz) δH (J in Hz) δH (J in Hz) 
1 0.70–0.80, m  0.70–0.80, m – – 0.71–0.80, m 
 1.79,dd (12.6,3.6) 1.79,dd (12.6,3.6) – – 1.79, d (12.4) 
2 1.23–1.30, m 1.23–1.30, m – – 1.26–1.42, m 
3 1.11–1.15, m  1.11–1.15, m – – 1.13, td (14.4,5.2)
 1.36–1.40, m 1.36–1.40, m – – 1.26–1.42, m 
5 0.70–0.80, m 0.70–0.80, m – – 0.71–0.80, m 
6 1.46–1.62, m 1.46–1.62, m – – 1.49–1.67, m 
7 1.46–1.62, m 1.46–1.62, m – – 1.49–1.67, m 
9 0.82–0.90, m 0.98–1.01, m – – 0.96–1.04, m 
11 1.46–1.62, m 1.46–1.62, m – – 1.49–1.67, m 
12 1.46–1.62, m 1.46–1.62, m – – 1.49–1.67, m 
13 2.37–2.42, m 2.51–2.58, m – – 2.54–2.56, m 
14 1.23–1.30, m 1.36–1.40, m – – 1.26–1.42, m 
 2.04, d (10.2) 2.09, d (10.4) – – 2.12, d (10.4) 
15 5.16, s 5.32, s – – 5.36, s 
17 3.97, d (13.7) 3.85, d (12.9) – – 4.190, s 
 4.13, d (13.7) 4.19, d (12.9) – – 4.194, s 
18 0.85, s 0.85, s – – 0.85, s 
19 0.80, s 0.80, s – – 0.80, s 
20 1.02, s 1.04, s – – 1.02, s 
2' 6.52–6.72, m 6.52–6.72, m 6.50–6.74, 0.6H, m 6.50–6.74, 0.4H, m – 
5' 6.52–6.72, m 6.52–6.72, m 6.50–6.74, 0.6H, m 6.50–6.74, 0.4H, m – 
6' 6.52–6.72, m 6.52–6.72, m 6.50–6.74, 0.6H, m 6.50–6.74, 0.4H, m – 
7' 2.41–2.45, m 2.51–2.58, m 2.40–2.45, 0.6H, m 2.57–2.68, 0.4H, m – 
 2.51–2.58, m 2.77, dd (13.2,9.6) 2.57–2.68, 0.6H, m 2.78, 0.4H, d (10.0) – 
8' 2.17–2.20, m 1.99–2.03, m 2.11–2.15, 0.6H, m 1.90–2.01, 0.4H, m – 
9' 4.83, s 4.81, d (4.7) 5.21, 0.6H, br s 5.21, 0.4H, br s – 
2''  6.52–6.72, m 6.52–6.72, m 6.50–6.74, 0.6H, m 6.50-6.74, 0.4H, m – 
5'' 6.52–6.72, m 6.52–6.72, m 6.50–6.74, 0.6H, m 6.50–6.74, 0.4H, m – 
6'' 6.52–6.72, m 6.52–6.72, m 6.50–6.74, 0.6H, m 6.50–6.74, 0.4H, m – 
7'' 2.41–2.45, m 2.41–2.45, m 2.57–2.68, 0.6H, m 2.40–2.45, 0.4H, m – 
 2.60–2.62, m 2.71, dd(13.2,4.9) 2.57–2.68, 0.6H, m 2.74, 0.4H, d (9.2) – 
8'' 2.11–2.12, m 2.37–2.42, m 2.11–2.15, 0.6H, m 2.40–2.45, 0.4H, m – 
9'' 3.64, dd (8.4,8.4) 3.57, dd (7.3, 7.3) 3.78, 0.6H, t (8.4) 3.56, 0.4H, t (8.0) – 
 3.96–4.00, m 3.96–4.00, m 3.93, 0.6H,dd (8.4,6.8) 4.09, 0.4H, t (8.1) – 
OCH2O 5.92–5.93, m 5.92–5.93, m 5.91–5.92, 2.4H, m 5.91–5.92, 1.6H, m – 
OH – – 2.95, 0.6H, br s 2.97, 0.4H, br s – 
 
 18
Table 7.  The 13C NMR (150 MHz, CDCl3) spectral data of A-I, 13, and 18. 
 A-I a A-I b 13a 13b 18 
position δC mult. δC mult. δC mult. δC mult. δC mult. 
1 40.4,a CH2 40.5,a CH2 – – 40.5, CH2
2 18.6, CH2 18.6, CH2 – – 18.6, CH2
3 42.1, CH2 42.1, CH2 – – 42.1, CH2
4 33.3, qC 33.3, qC – – 33.3, qC 
5 55.9, CH 56.0, CH – – 56.0, CH 
6 19.3, CH2 19.3, CH2 – – 19.2, CH2
7 39.2, CH2 39.2, CH2 – – 39.3, CH2
8 49.0, qC 49.0, qC – – 49.0, qC 
9 48.2, CH 48.5, CH – – 48.4, CH 
10 39.6, qC 39.6, qC – – 39.5, qC 
11 18.6, CH2 18.6, CH2 – – 18.6, CH2
12 25.3, CH2 25.6, CH2 – – 25.7, CH2
13 41.1, CH 41.7, CH – – 41.2, CH 
14 43.6, CH2 43.8, CH2 – – 43.9, CH2
15 137.8, CH 137.4, CH – – 136.1, CH 
16 142.7, qC 143.2, qC – – 145.9, qC 
17 64.4, CH2 65.2, CH2 – – 61.3, CH2
18 33.6, CH3 33.6, CH3 – – 33.6, CH3
19 21.6, CH3 21.6, CH3 – – 21.6, CH3
20 17.7, CH3 17.7, CH3 – – 17.7, CH3
1' 134.1,a qC 134.9,a qC 133.3, qC 134.5, qC – 
2' 109.2, CH 109.3, CH 108.1, CH 108.2, CH – 
3' 147.7,a qC 147.6,a qC 147.6, qC 147.7, qC – 
4' 145.8,a qC 145.9,a qC 145.9, qC 146.0,aqC – 
5' 108.1, CH 108.1, CH 109.2, CH 108.9, CH – 
6' 121.7, CH 121.6, CH 121.8, CH 121.6, CH – 
7' 38.8, CH2 33.7, CH2 39.2, CH2 33.6, CH2 – 
8' 52.4, CH 52.2, CH 53.1, CH 52.0, CH – 
9' 107.0, CH 104.1, CH 103.4, CH 98.8, CH – 
1'' 133.6,a qC 134.3,a qC 134.1, qC 133.9, qC – 
2''  109.0, CH 109.0, CH 108.9, CH 108.2, CH – 
3'' 147.5,a qC 147.5,a qC 147.6, qC 147.5, qC – 
4'' 145.7,a qC 145.6,a qC 145.8, qC 145.7, qC – 
5'' 108.1, CH 108.1, CH 108.1, CH 109.3, CH – 
6'' 121.4, CH 121.4, CH 121.4, CH 121.4, CH – 
7'' 39.2, CH2 39.5, CH2 38.4, CH2 38.9, CH2 – 
8'' 45.9, CH 43.4, CH 45.9, CH 42.9, CH – 
9'' 71.9, CH2 72.2, CH2 72.2, CH2 72.6, CH2 – 
2 × OCH2O 100.8, CH2 100.8, CH2 100.8, CH2 100.8, CH2 – 
aAssignments in the same line are interchangeable 
 2.2.2 Identification of compound A-II 
Compound A-II was obtained as an optically active pale brown solid ([α]D23.9 -43.2 (c 0.057, 
CHCl3 )), with melting point of 162-164 oC. In the EIMS spectrum, compound A-II gave a 
molecular ion peak at m/z 356 (50.9%). The molecular formula of compound A-II was assigned 
as C20H20O6 based on the 1H and 13CNMR spectra and the EIMS, defining 11 degrees of 
unsaturation. The FT-IR spectrum of compound A-II displayed bands due to hydroxyl group at 
3411 cm-1 and lactone moiety at 1760 cm-1.  
 
Figure 8. Structure of compound A-II and (-)-hinokinin 
 
The 1HNMR spectrum of compound A-II showed one methoxyl group at δH 3.85 (3H, s, 
OCH3), and six aromatic protons at δH 6.45 (1H, s, H-2'), 6.46 (1H, d, J = 1.9 Hz), 6.62 (1H, dd, 
J = 8.3, 1.9 Hz), 6.66 (1H, d, J = 1.9 Hz), 6.69 (1H, d, J = 7.7 Hz), and 6.83 (1H,d , J = 8.0 Hz). 
The 13CNMR spectrum of compound A-II showed twenty carbon resonances, including one 
carbonyl carbon (δc 178.7) and one methoxyl carbon (δc 55.9) (Table 8). 
The NMR spectra of compound A-II were similar to those of compound (–)-hinokinin (14), 
2D NMR techniques such as HMQC, HMBC, and NOE allowed the unambiguous assignment of 
all 1H and 13CNMR resonances in compound A-II. Position of the methoxyl and hydroxyl group 
was deduced by HMBC correlations between the methoxyl-hydrogens (δH 3.85) and the 
3-carbon (δc 146.3), and hydroxyl-hydrogens (δH 5.53) and the 3, 4, 5-carbons (δc 146.3, 144.5, 
and 114.2) (Figure 9). Thus, compound A-II was assigned to be (-)-pluviatolide22 (Figure 8). 
 
 
 
Figure 9. Selected HMBC correlations of compound A-II 
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Table 8. 1H and 13CNMR spectral data of compound A-II 
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position δC δH  (J in Hz) 
1 129.4  
2 111.5 6.66, d (1.9) 
3 146.3  
4 144.5  
5 114.2 6.83, d (8.0) 
6 122.1 6.62, dd (8.3, 1.9) 
7 34.6 2.90, dd (14.0, 6.9), 2.96, dd (14.0, 5.2) 
8 46.6 2.53-2.57, m  
9 178.7  
1' 131.6  
2' 108.8 6.45, s  
3' 147.9  
4' 146.7  
5' 108.3 6.69, d (7.7) 
6' 121.5 6.46, d (1.9) 
7' 38.3 2.59-2.61, m, 2.45-2.50, m 
8' 41.0 2.45-2.50, m 
9' 71.2 3.84-3.87, m, 4.11, dd (9.0, 7.1) 
OCH2O 101.0 5.93-5.94, m  
OCH3 55.9 3.85, s  
OH  5.53, s  
 
 
 
 
 
 
 
 
 
 
 
2.2.3 Identification of compound A-III 
Compound A-III was obtained as a colorless oil. Molecular formular was determined to be 
C12H14O2 due to a molecular ion peak of EIMS spectrum at m/z 190 (51.2%).  
 
Figure 10. Structure of compound A-III 
 
The 1HNMR spectrum of compound A-III indicated the presence of aliphatic secondary 
methyl signal at δH 1.36 (3H, d, J= 7.0 Hz, H-9), two singlets at δH 6.69 (1H, s, H-5) and 7.85 
(1H, s, H-8) were assigned to protons of the para position of a benzene ring. In addition, an 
aromatic methyl signal (δH 2.25) was observed. 
On the basis of the above analyses, compound A-III was assigned as aristelegone-A (Figure 
10), which was separated from A. elegans by Wu in 2002.29
 
 
2.2.4 Identification of compound A-IV 
Compound A-IV was obtained as a brown solid with melting point of 251-263 oC, the 
HREIMS of which showed a molecular ion at m/z 279.0869 consistent with the molecular 
formula C17H13NO3。 The IR absorptions at 1716 cm-1 was attributable to amide carbonyl. 
 
 
Figure 11. Structure of compound A-IV 
 
The 1HNMR spectrum of compound A-IV showed two methoxyl groups at δH 4.09 and 4.13, 
and six aromatic protons at δH 7.10 (1H, s, H-9), 7.59 (2H, m, H-6, H-7), 7.83 (2H, m, H-2, H-8), 
and 9.23 (1H, m, H-5) (Table 9). Comparison with the reference of the proton shift of 
aristolochia derivatives, compound A-IV was assigned to be cepharanone B24 (Figure 11). 
 
Table 9. 1H NMR spectral data of compound A-IV 
   position δH  (J in Hz) (CDCl3) δH  (J in Hz) (DMSO)24
2 7.83, m 6.79, d, (8.2) 
5 9.23, m 9.13, d (8.0) 
6 7.59, m 7.59, m 
7 7.59, m 7.59, m 
8 7.83, m 7.98, d (8.0) 
9 7.10, s 7.16, s 
OCH3 4.09, s 4.05, s 
OCH3 4.13, s 4.06, s 
 
 
 
 
 
 
 
 
 
 
 
2.2.5 Identification of compound A-V 
Compound A-V was obtained as an optically active pale brown solid ([α]D25.1 -31.6) with 
melting point of 107-110 oC. In the EIMS spectrum, compound A-V gave a molecular ion peak 
at m/z 358 (10.5%). The molecular formula of compound A-V was assigned as C20H22O6 based 
on 1HNMR spectra and EIMS, defining 10 degrees of unsaturation. The IR spectrum of 
compound A-V displayed bands due to hydroxyl groups at 3419 cm-1.  
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Figure 12. Structure of compound A-V 
 
The 1HNMR spectrum and the molecular formula of compound A-V suggested a symmetric 
structure, which was deduced by the proton integration of 1HNMR and the molecular formula 
(C20H22O6), Six aromatic proton δH 6.60 (2H, d, J=7.7 Hz, Ar-H), 6.64 (2H, s, Ar-H), and 6.71 
(2H, d, J=7.7 Hz, Ar-H), and two typical methylenedioxy group at δH 5.92-5.96 (4H, m, OCH2O), 
together with the prominent peak at m/z 135 (100%) in the EIMS, two methylenedioxybenzyl 
group can be deduced (Table 10). 
The spectral data of compound A-V were very similar to those of compound 
(-)-dihydrocubebin,25 including the optical rotation ([α]D28 -36.8), Thus, compound A-V was 
assigned to be (-)-dihydrocubebin (Figure 12). 
 
               Table 10. 1H NMR spectral data of compound A-V 
   position δH  (J in Hz) (400 MHz) δH  (J in Hz)25 (60 MHz) 
7/7’ 2.61, 2H, dd (13.7, 5.8) 2.66, 4H, d (7.0) 
 2.75, 2H, dd (13.7, 8.8)  
8/8’ 1.84, 2H, s 1.85, 2H, m 
9/9’ 3.49, 2H, dd (11.3, 3.8) 3.6, 6H, m 
 3.78, 2H, d (11.3)  
OCH2O 5.92-5.96, 4H, m 5.90, 4H, s 
Ar-H 6.60, 2H, d (7.7) 6.62, 6H, s  
 6.64, 2H, s   
 6.71, 2H, d (7.7)  
 
 
 
 
 
 
 
 
 
 
 
2.2.6 Identification of compound A-VI 
Compound A-VI was obtained as an optically active amorphous solid ([α]D23.5 -42.0). In the 
EIMS spectrum, compound A-VI gave a molecular ion peak at m/z 358 (10.5%), together with 
two prominent peaks at m/z 137 (81%) and 135(59%) due to hydroxymethoxybenzyl and 
methylenedioxybenzyl cations, respectively. The molecular formula of compound A-VI was 
assigned as C20H22O6. The IR spectrum of compound A-VI displayed bands due to hydroxyl 
group at 3394 cm-1. 
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 Figure 13. Structure of compound A-VI 
The 1HNMR spectrum of compound A-VI looked like cubebin (13), except the replacement 
of one methylenedioxy in 13 to one hydroxyl and one methoxyl groups indicated the presence of 
an epimeric mixture. The ratio of the epimers was deduced to be 3:2 based on the 1HNMR 
spectrum (Table 11).  
Thus, compound A-VI was assigned to be (-)-haplomyrfolol26 (Figure 13). 
 
Table 11. 1H and 13CNMR spectral data of compound A-VI 
H Compound A-VI 
δH  (J in Hz) 
(-)-haplomyrfolol-a 
 δH (J in Hz)26
δC26 (-)-haplomyrfolol-b 
 δH (J in Hz)26
δC26
1   133.32  134.53
2 6.49-6.84 m, 6H, Ar-H 6.55, 0.6H, d (1.5) 109.14 6.74, 0.4H, d (1.5) 109.29
3   147.60  147.49
4   145.85  145.68
5 6.49-6.84 m, 6H, Ar-H 6.68, 0.6H, d (7.6) 107.98 6.72, 0.4H, d (7.9) 108.10
6 6.49-6.84 m, 6H, Ar-H 6.54, 0.6H, dd (8.0, 1.5) 121.71 6.68, 0.4H, dd (7.9, 1.5) 121.56
7 2.57-2.80, m 2.42, 0.6H, m  
2.65, 0.6H, m 
38.39 2.61, 0.4H, m 
2.78, 0.4H, m 
33.61
8 2.00, m, 0.4H; 2.15, m, 0.6H 2.15, 0.6H, m 53.10 2.00, 0.4H, m 52.04
9 5.23, s 5.22, 0.6H, d (1.6) 103.36 5.24, 0.4H, d (4.5) 98.83
1’   132.23  131.92
2’ 6.49-6.84 m, 6H, Ar-H 6.51, 0.6H, d (1.8) 111.07 6.61, 0.4H, d (1.8) 111.03
3’   146.34  146.46
4’   143.85  144.00
5’ 6.49-6.84 m, 6H, Ar-H 6.79, 0.6H, d (8.0) 114.25 6.82, 0.4H, d (7.9) 114.32
6’ 6.49-6.84 m, 6H, Ar-H 6.56, 0.6H, dd (8.0, 2.0) 121.17 6.63, 0.4H, dd (8.0, 1.8) 121.20
7’ 2.57-2.80, m 2.59, 0.6H, m 
2.62, 0.6H, m 
39.15 2.45, 0.4H, m 
2.77, 0.4H, m 
38.82
8’ 2.17, m, 0.6H; 2.45, m, 0.4H 2.17, 0.6H, m 45.99 2.45, 0.4H, m 42.88
9’a 4.10, t (7.9) 0.4H;    
3.79, t (7.7), 0.6H 
3.80, 0.6H, t (8.3) 72.24 4.09, 0.4H, t (8.2) 72.63
9’b 4.00, dd (8.4, 7.0), 0.6H; 
3.57, t (7.3), 0.4H 
4.00, 0.6H, dd (8.6, 7.1)  3.58, 0.4H, t (8.3)  
OCH3 3.84, 1,2H; 3.87, 1.8H 3.83, 1.8H, s 55.79 3.87, 1.2H, s 55.87
OCH2O 5.91, m 5.905, 5.908, 1.2H 100.83 5.911, 5.914, 0.8H, 100.74
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 2.2.7 Identification of compound A-VII 
Compound A-VII showed a molecular ion at m/z 313 (5%) consistent with the molecular 
formula C18H19NO4. It was obtained as a brown solid with melting point of 99-103 oC. The IR 
absorptions at 1650 cm-1 was attributable to α,β-unsaturated amide carbonyl. 
 
Figure 14. Structure of compound A-VII 
 
 
The 1HNMR spectrum of compound A-VII showed one methoxyl group at δH 3.89 (3H, s 
OCH3), and olefinic protons at δH 7.49 (1H, d, J= 15.6 Hz) and δH 6.20 (1H, d, J= 15.6 Hz) 
deducible to be E configuration (Table 12). HMQC, HMBC, and DEPT techniques were then 
used to assist the interpretation of the structure of this compound, allowing unambiguous 
assignment of all 1H and 13CNMR resonances in compound A-VII. Position of the methoxyl was 
deduced by HMBC correlations between the methoxyl-hydrogens (δH 3.89) and the 3’-carbon 
(δc 147.3). Thus, compound A-VII was assigned to be N-trans-feruloyltyramine23 (Figure 14). 
 
Table 12.  1H and 13CNMR spectral data of compound A-VII 
   position δC δH  (J in Hz) 
 1 129.9  
 
2 129.8 7.05, d (8.2) 
 
3 115.5 6.79, d (8.2) 
 
4 155.3  
 
5 115.5 6.79, d (8.2) 
 
6 129.8 7.05, d (8.2) 
 
7 34.7 2.78, t (6.8) 
 
8 41.0 3.57, t (6.8) 
 
1' 127.0  
 
2' 110.2 6.98, brs  
3' 147.3   
4' 148.0   
5' 115.2 6.86, d (8.2)  
6' 122.2 7.01, d (8.2)  
7' 141.2 7.49, d (15.6)  
8' 117.7 6.20, d (15.6)  
C=O 167.1   
55.9 OCH3 3.89, s  
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 2.2.8 Identification of compound A-VIII 
Compound A-VIII was obtained as a colorless amorphous gum. In the FABMS spectrum, 
compound A-VIII gave a pseudo-molecular ion peak at m/z 715 [M+H]+. The molecular formula 
of compound A-VIII was assigned as C40H42O12. The IR spectrum of compound A-VIII 
displayed bands due to hydroxyl group at 3442 cm-1 and ester group at 1693 cm-1.  
 
Figure 15.   Structure of compound A-VIII 
 
Table 13. 1H and 13CNMR spectral data of compound A-VIII 
   
position δC δH   (J in Hz)  
1 and 1' 131.8  
 
2 and 2' 111.3 6.52, s 
 
3 and 3' 146.5   
4 and 4' 143.9   
5 and 5' 114.1 6.80, d (8.0)  
6 and 6' 121.8 6.61, d (8.0)  
7 and 7' 35.4 2.72, m  
8 and 8' 40.2 2.21, t (5.8) 
9 and 9' 64.6 
4.38, dd (11.3, 8.0),  
 
 
4.21, dd (11.3, 5.2)  
1'' and 1''' 126.9   
2'' and 2''' 109.5 7.01, s  
3'' and 3''' 146.8   
4'' and 4''' 148.1   
5'' and 5''' 114.7 6.91, d (8.2)  
6'' and 6''' 123.2 7.06, d (8.2)  
7'' and 7''' 145.2 7.58, d (15.7)  
8'' and 8''' 115.2 6.28, d (15.7)  
3 and 3' –OCH3 56.1 3.77, s  
3'' and 3''' –OCH3 55.7 3.92, s  
 9'' or 9''' (C=O) 167.4  
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The 1H and 13CNMR spectra of compound A-VIII suggested the presence of a symmetric 
structure. Two AB sets of signals at δH 6.28 (1H, d, J=15.7 Hz, H-7'' or 7'''), and 7.58 (1H, d, 
J=15.7 Hz, H-8'' or 8''') with large coupling constant for two trans vinylic systems, and two 
three-proton singlet at δH 3.92 (3H, s, H-7'' or 7''' ) indicated that compound A-VIII has two 
feruloyl moieties (Table 13). The HMBC correlations between H-9 or 9' [δH 4.38 (1H, dd, J=11.3, 
8.0 Hz), 4.21 (1H, dd, J=11.3, 5.2 Hz) and C-9'' or 9''' (δ 167.4) confirmed the connections of 
these feruloyl moieties at C-9 or 9'. These data were very similar to those of 
9,9',-O-feruloyl-(-)-secoisolariciresinol,28 which showed strong cytotoxic activity against human 
lung carcinoma and breast carcinoma cell lines in an cytotoxicity assay with EC50 values of 1.8 
and 3.9 μg/ml, respectively. Thus, compound A-VIII was assigned to be 
9,9',-O-feruloyl-(-)-secoisolariciresinol (Figure 15). 
 
 
2.2.9 Identification of compound A-IX 
Compound A-IX was obtained as a brown solid with melting point of 251-263 oC. In the 
EIMS spectrum, compound A-IX gave a molecular ion peak at m/z 342 (23.6%). The molecular 
formula of compound A-IX was assigned as C20H23NO4. The IR spectrum of compound A-IX 
displayed bands due to hydroxyl group at 3332 cm-1. 
 
Figure 16. Structure of compound A-IX 
 
The 1HNMR spectrum of compound A-IX indicated the presence of two methoxy groups at 
δH 3.66 and 3.72, together with two N-methyl groups at δH 2.70 and 3.14 (Table 14). 2D NMR 
(HMQC, HMBC, and COSY) study led to unambiguous assignment of all functional groups. 
Position of the two methoxy group was deduced by HMBC correlations between the 
12-methoxyl-hydrogens (δH 3.66) and the 3-carbon (δc 153.2), 13-methoxyl-hydrogens (δH 3.72) 
and the 10-carbon (δc 151.8). 
These data allowed us to deduce compound A-IX to be magnoflorine27 (Figure 16). 
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Table 14. 1H and 13CNMR spectral data of compound A-IX 
   position δC δH  (J in Hz) 
1  150.9  
2 
 
153.2  
3 
 
109.6 6.37, s  
3a 
 
115.8  
4 
 
24.7 3.02, m, 2.51, d (17.3) 
5 
 
62.4 3.37, m 
6a 
 
71.2 3.75, m 
7 
 
31.7 2.85, d (12.4), 2.35, t (12.9) 
7a 
 
126.1  
8 
 
117.0 6.38, d (7.2) 
9 
 
110.8 6.57, d (8.0) 
10 
 
151.8  
11 
 
150.0  
11a 
 
123.7  
11b 
 
123.6  
11c 
 
121.1  
12 (OCH3) 
 
56.4 3.66, s 
13 (OCH3) 
 
56.4 3.72, s  
14 (NCH3) 43.6 2.70, s  
15 (NCH3) 54.0 3.14, s   
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Chapter 3. Bioactivity of Isolated Compounds. 
3.1 Antispasmodic activities  
 
The antispasmodic effects of the 11 isolated constituents [five lignans: (-)-cubebin (13), 
(-)-hinokinin (14), (-)-pluviatolide (A-II), (-)-dihydrocubebin (A-V), and (-)-haplomyrfolol 
(A-VI); three diterpenes: (-)-kauran-16α,17-diol (16), (-)-kaur-16-en-19-oic acid (17), and 
(-)-kaur-15-en-17-ol (18); and three others: the new diterpeno-lignan hybrid (A-I), aristolochic 
acid-1 (7), and (+)-4,7-dimethyl-6-methoxy-1-tetralone (16)] on ECI and AChI contractions were 
studied in guinea-pig ileum (Figure 17 and 18). The Ca2+ channel blocker verapamil was also 
examined as a positive control. The IC50 values for the antispasmodic effects of the tested 
samples are summarized in Table 15.   
Four lignans [(-)-cubebin (13), (-)-hinokinin (14), (-)-pluviatolide (A-II), and 
(-)-haplomyrfolol (A-VI)] and (-)-kaur-16-en-19-oic acid (17) markedly and significantly 
inhibited ECI and AChI contractions to the same extent. In addition, verapamil also inhibited 
these contractions with similar potency. In our antispasmodic test, acetylcholine (ACh) acts on 
the muscarinic M3 receptors on smooth muscle cells, leading to the induction of ileal contraction, 
whereas electrical stimulation excites the parasympathetic postsynaptic neurons to elicit Ach 
release from the nerve endings.30 Because (-)-cubebin (13), (-)-hinokinin (14), (-)-pluviatolide 
(A-II), (-)-haplomyrfolol (A-VI), and (-)-kaur-16-en-19-oic acid (17) have an inhibitory effect 
on both ECI and AChI contractions, these constituents are thought to inhibit the mechanism of 
smooth muscle contraction.30   
0
20
40
60
80
100
120
140
160
A-I 13 18 14 A-II A-VI AV 17 16 7 15
Compound
C
on
tr
ac
tio
n 
(%
)
10 μM
30 μM
100 μM
b b
b
b
b
b
bb
b
  
Figure 17.  Effects of the selected isolates of A. constricta on ECI contraction in isolated guinea-pig ileum.  
Contraction (%) is expressed as a percentage against control contraction induced by electrical stimulation in 
the absence of samples.  Each value shows mean ± S.E.M of four to five animals.  a P < 0.05, b P < 0.01, 
significantly different from control contraction(%) (paired t-test)  
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Figure 18.  Effects of the selected isolates of A. constricta on AChI contraction in isolated guinea-pig ileum.  
Contraction (%) is expressed as a percentage against control contraction induced by Ach in the absence of 
samples.  Each value shows mean ± S.E.M of four to five animals.  a P < 0.05, b P < 0.01, significantly 
different from control contraction (%) (paired t-test) 
 
We found that aristolochic acid-1 (7) potently inhibited ECI contraction, but barely 
inhibited AChI contraction in the guinea-pig ileum preparation (Figures 17 and 18). The site of 
action for aristolochic acid-I (7) may differ from those for the above five isolates. Aristolochic 
acid-1 (7) preferentially inhibits the neurogenic contraction rather than the contraction elicited by 
activation of the muscarinic M3 receptors in smooth muscle cells. Therefore, aristolochic acid-I 
(7) is thought to have an inhibitory effect on the neurotransmitter release in the gut. 
 
Table 15.  IC50 Values of constituents of A. constricta to inhibit ECI and AChI contractions in isolated 
guinea-pig Ileum 
 
Compounds ECI Contraction (μM) AChI Contraction (μM) 
A-I 
 
> 100.0 > 100.0 
13 
 
51.6 ± 4.5 23.6 ± 4.5 
18 
 
34.1 ± 4.2 > 100.0 
14 
 
69.8 ± 5.9 27.3 ± 5.9 
A-II 
 
58.3 ± 10.1 26.8 ± 10.1 
A-VI 
 
52.8 ± 6.4 39.5 ± 6.4 
A-V 
 
> 100.0 40.4 ± 8.5 
17 
 
28.2 ± 8.5 25.4 ± 4.2 
16 
 
> 100.0 > 100.0 
7 
 
64.0 ± 14.1 > 100.0  
> 100.0 89.8 ± 18.7 15  
Verapamil 0.25 ± 0.05 0.28 ± 0.03  
 
Each value shows mean ± S.E.M of four to five animals 
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It has been reported that (-)-kaur-16-en-19-oic acid (17), which inhibited both ECI and 
AChI contractions in the present study, shows an antispasmodic activity31 and that the presence 
of a carboxylic acid function in the molecule is important for the inhibitory activity.31c In fact, 
the kaurenoic acid (17) is an interesting compound showing a variety of pharmacological actions, 
including cytotoxicity,32 inhibition of protein tyrosine phosphatase 1B,33 genotoxicity,34 
antimicrobial activity,35 antiproliferative activity,36 and reduction of sperm motion.37 On the other 
hand, dibenzyldihydrofuran-type lignans such as (-)-cubebin (13) and (-)-hinokinin (14) show a 
variety of pharmacological actions: trypanocidal activity,38 analgesic activity,39 
anti-inflammatory activity,39b, 39c, 40 antigenotoxicity,41 oral pathogenicity,42 cytotoxicity,43 
antiproliferative activity,44 antiviral activity,45 insecticidal activity,46 cytochrome P450 
inhibition,47 and melanogenesis stimulation activity.48 Thus, the antispasmodic activity of 
(-)-cubebin (13), (-)-hinokinin (14), and (-)-pluviatolide (A-II) observed in our study presents an 
additional pharmacological action for the dibenzyldihydrofuran-type lignans. The importance of 
the carboxylic acid function in the kaurenoic acid (17)33c suggests that the lactol and lactone 
functions in the lignan structures may act as key functions for the activity. In the present study, 
although (-)-cubebin (13) carrying a lactol function has a potent antispasmodic activity, 
9-O-[(-)-kaur-15-en-17-oxyl]cubebin (A-I), in which a lactol in the cubebin moiety was 
protected as an ether tether, did not show any antispasmodic activity. Therefore, the lactol or 
lactone function in the lignan structures may work as a pharmacophore for the antispasmodic 
activity. 
In conclusion, the hexane and CHCl3 extracts of A. constricta showed relaxant activities 
against ECI and AChI contractions in the isolated guinea-pig ileum. (-)-Cubebin (13), 
(-)-hinokinin (14), (-)-pluviatolide (A-II), (-)-haplomyrfolol (A-VI), and (-)-kaur-16-en-19-oic 
acid (17) have antispasmodic effects, probably due to the inhibition of the mechanism of smooth 
muscle contraction. Aristolochic acid-1 (7) shows an antispasmodic effect, probably through the 
inhibitory effect on neurotransmitter release in the gut. These pharmacological effects may 
validate the use of “Saragosa” as an antispasmodic in folk medicine. The present results are at 
variance with previous reports,16a, 16c–e in which protopine-type alkaloids isolated from the EtOH 
extract had been identified as the active principals; however, the reason for this discrepancy is 
not clear.  In addition, 9-O-[(-)-kaur-15-en-17-oxyl]cubebin (A-I) was isolated as a new 
diterpeno-lignan hybrid, although it did not exhibit antispasmodic activity. 
 
 
 
 
 
 
 
 
 
 
 
 
3.2 Cytotoxicity of the Isolated Compounds 
 
The cytotoxicity of the 7 isolated constituents [four lignans: (-)-hinokinin (14), 
(-)-pluviatolide (A-II), (-)-dihydrocubebin (A-V), and (-)-haplomyrfolol (A-VI); and three others: 
aristolochic acid-1 (7), (+)-4,7-dimethyl-6-methoxy-1-tetralone (15), and 
N-trans-feruloyltyramine (A-VII) ] were examined by brine shrimp bioassay and the results are 
shown in Figure 19. Berberine was also examined as a positive control. The death ratio of  
shrimps were counted after 12 h, 24 h, and 48 h, and (-)-hinokinin(14), aristolochic acid-1(7), 
and N-trans-feruloyltyramine (A-VII) showed cytotoxicity in these experiments. 
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Figure 19. Brine shrimp bioassay of isolated compounds  
1: (-)-Hinokinin (14), 2: (-)-Pluviatolide (A-II), 3: (-)-Dihydrocubebin (A-V), 4: (-)-Haplomyrfolol (A-VI), 5: Aristolochic acid-1 
(7), 6: (+)-4,7-Dimethyl-6-methoxy-1-tetralone (15), 7: N-trans-feruloyl tyramine (A-VII), 8: Berberine 
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Chapter 4. Conclusion 
 
Eighteen constituents, in which include two compounds by Mochizuki and six compounds 
by Shimokawa, were isolated from the chloroform and ethanol extracts of A. constricta, the 
aerial parts of which has been empirically used in folk medicine for various purposes. 
9-O-[(-)-kaur-15-en-17-oxyl]cubebin was isolated as a new diterpeno-lignan hybrid, The 
inhibitory effects of these constituents on smooth muscle contraction in isolated guinea-pig ileum 
were studied 3,4-Dibenzyldihydrofuran-type lignans [(-)-cubebin, (-)-hinokinin, and 
(-)-pluviatolide] and a kaurene-type diterpene [(-)-kaur-16-en-19-oic acid] were isolated as active 
principles, however the new diterpeno-lignan hybrid did not show antispasmodic activity. 
(-)-hinokinin, aristolochic acid-1, and N-trans-feruloyltyramine also showed cytotoxicity assay 
using brine shrimp. 
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Chapter 5 Experimental Section 
 
 
General Experimental Procedures. Melting points were determined on a micromelting point 
hot-stage instrument (Yanagimoto) and are uncorrected. IR spectra were recorded on a JASCO 
IR-300 E spectrophotometer. Optical rotations were recorded on a JASCO DIP-360 polarimeter. 
EIMS were measured on a JEOL GC-Mate spectrometer. 1H and 13C NMR spectra were recorded 
with JEOL JNM ECP 400 and 600 spectrometers with tetramethylsilane as an internal reference. 
For column chromatography (CC) and flash chromatography (FC), silica gel 60 (70–230 mesh 
ASTM; Merck) and silica gel 60 (230–400 mesh ASTM; Merck) were used, while for TLC and 
preparative TLC (P-TLC), silica gel 60 F254 (Merck) was used. A Biotage C18HS 12+M column 
was used for reverse-phase flash chromatography (RFC). 
 
Plant material.  The stem part of A. constricta was collected at Mocache, LosRios province in 
the coastal region of Ecuador in 2004, the plant material being verified by Prof. Enrique Torres 
Bolanos (Facultad de Ciencias Químicas, Universidad de Guayasquil, Ecuador) (BETB-1). 
 
Extraction and isolation. Dried and powered plant material (413 g) was successively extracted 
using a Soxhlet apparatus with hexane, CHCl3, and EtOH as solvent and, after evaporation of the 
solvent, gave each extract. A part (295 mg) of the hexane extract was subjected to CC followed 
by washing with hexane–Et2O to afford (-)-cubebin (13) (21 mg). The CHCl3 extract (7.83 g) 
was washed with hexane followed by washing the insoluble fraction with Et2O to give three 
fractions [hexane-soluble (Fr. A, 2.71 g), Et2O-soluble (Fr. B, 2.44 g), and Et2O-insoluble (Fr. C, 
1.56 g) fractions]. The Et2O-insoluble fraction was further divided into two fractions by washing 
with MeOH [MeOH-soluble (Fr. D, 0.837 g) and MeOH-insoluble (Fr. E, 0.602 g) fractions]. 
These four fractions (Fr. A–D) were subjected to repeated separations using CC, FC, and p-TLC 
using various solvent systems, and the isolated components are noted in order of polarity as 
follows. Five components were isolated from Fr. A [(-)-kaurene (7 mg), 
(-)-9-[(-)-kaur-15-en-17-oxyl]cubebin (A-I) (5 mg), 9-O-methylcubebin (3 mg), 
(-)-kaur-16-en-19-oic acid (17) (170 mg), and (-)-kaur-15-en-17-ol (18) (68 mg)], thirteen 
components from Fr. B [(-)-kaur-16-en-19-oic acid (17) (15 mg), (-)-hinokinin (14) (26 mg), 
(+)-4,7-dimethyl-6-methoxy-1-tetralone (15) (30 mg), (-)-kaur-15-en-17-ol (18) (22 mg), 
(-)-pluviatolide (A-II) (10 mg), aristelegone-A (A-III) (2 mg), (-)-cubebin (13) (168 mg), 
cepharanone B (5 mg), (-)-dihydrocubebin (A-V) (8 mg), (-)-haplomyrfolol (A-VI) (11 mg), 
(-)-kauran-16α,17-diol (16) (58 mg), aristololactam A II (6 mg), and N-trans-feruloyl tyramine 
(A-VII) (7 mg)], four components from Fr. D [aristolochic acid-I (7) (15 mg), aristololactam A II 
(4 mg), N-trans-feruloyl tyramine (A-VII) (16 mg), and β-sitosterol glycoside (5 mg)], and one 
component [aristolochic acid-I (7) (433 mg)] from Fr. E. two components from EtOH ext 
[9,9',-O-feruloyl-(-)-secoisolariciresinol (A-VIII) and Magnoflorine (V-IX)]. 
 
(–)-9-[(–)-Kaur-15-en-17-oxyl]cubebin (A-I). Obtained as a colorless amorphous gum; [α]24D 
–10.9 (c 0.11, CHCl3); IR (ATR) νmax 3440, 2921, 1737 cm–1; EIMS m/z 626 [M]+ (13), 355 (24), 
288 (9).  
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(-)-(5R,8R,9S,10R,13S,8'R,9'S,8''S)-9'-(Kaur-15-en-17-oxy)-cubebin. 1H (CDCl3, 600 MHz) δ 
0.70-0.80 (2H, m, H-1, H-5), 0.80 (3H, s, H-19), 0.85 (3H, s, H-18), 0.82-0.90 (1H, m, H-9), 
1.02 (3H, s, H-20), 1.11-1.15 (1H, m, H-3), 1.23-1.30 (3H, m, H-2, H-14), 1.36-1.40 (1H, m, 
H-3), 1.46-1.62 (8H, m, H-6, H-7, H-11, H-12), 1.79 (1H, dd, J=12.6, 3.6 Hz, H-1), 2.04 (1H, d, 
J=10.2 Hz, H-14), 2.11-2.12 (1H, m, H-8''), 2.17-2.20 (1H, m, H-8'), 2.37-2.42 (1H, m, H-13), 
2.41-2.45 (2H, m, H-7', H-7''), 2.51-2.58 (1H, m, H-7'), 2.60-2.62 (1H, m, H-7''), 3.64 (1H, dd, 
J=8.4, 8.4 Hz, H-9''), 3.96-4.00 (1H, m, H-9''), 3.97 (1H, d, J=13.7 Hz, H-17), 4.13 (1H, d, 
J=13.7 Hz, H-17), 4.83 (1H, s, H-9'), 5.16 (1H, s, H-15), 5.92-5.93 (4H, m, OCH2O), 6.52-6.72 
(6H, m, H-2', H-5', H-6', H-2'', H-5'', H-6'') ; 13C NMR (CDCl3, 150 MHz) δ 17.7 (C-20), 18.6 
(C-2), 18.6 (C-11), 19.3 (C-6), 21.6 (C-19), 25.3 (C-12), 33.3 (C-4), 33.6 (C-18), 38.8 (C-7'), 
39.2 (C-7''), 39.2 (C-7), 39.6 (C-10), 40.4 (C-1), 41.1 (C-13), 42.1 (C-3), 43.6 (C-14), 45.9 
(C-8''), 48.2 (C-9), 49.0 (C-8), 52.4 (C-8'), 55.9 (C-5), 64.4 (C-17), 71.9 (C-9''), 100.8 (2OCH3O), 
107.0 (C-9'), 108.1 (C-5'), 108.1 (C-5''), 109.0 (C-2''), 109.2 (C-2'), 121.4, (C-6''), 121.7 (C-6'), 
133.6 (C-1''), 134.1 (C-1'), 137.8 (C-15), 142.7 (C-16), 145.8 (C-4'), 145.7 (C-4''), 147.5 (C-3''), 
147.7 (C-3').  
(-)-(5R,8R,9S,10R,13S,8'R,9'R,8''S)-9'-(Kaur-15-en-17-oxy)-cubebin. 1H (CDCl3, 600 MHz) 
δ 0.70-0.80 (2H, m, H-1, H-5), 0.80 (3H, s, H-19), 0.85 (3H, s, H-18), 0.98-1.01 (1H, m, H-9), 
1.04 (3H, s, H-20), 1.11-1.15 (1H, m, H-3), 1.23-1.30 (2H, m, H-2), 1.36-1.40 (2H, m, H-3, 
H-14), 1.46-1.62 (8H, m, H-6, H-7, H-11, H-12), 1.79 (1H, dd, J=12.6, 3.6 Hz, H-1), 1.99-2.03 
(1H, m, H-8'), 2.09 (1H, d, J=10.4 Hz, H-14), 2.37-2.42 (1H, m, H-8''), 2.41-2.45 (1H, m, H-7''), 
2.51-2.58 (2H, m, H-7', H-13), 2.71 (1H, dd, J=13.2, 4.9 Hz, H-7''), 2.77 (1H, dd, J=13.2, 9.6 Hz, 
H-7'), 3.57 (1H, dd, J=7.3, 7.3 Hz, H-9''), 3.85 (1H, d, J=12.9 Hz, H-17), 3.96-4.00 (1H, m, H-9''), 
4.19 (1H, d, J=12.9 Hz, H-17), 4.81 (1H, d, J=4.7 Hz, H-9'), 5.32 (1H, s, H-15), 5.92-5.93 (4H, 
m, OCH2O), 6.52-6.72 (6H, m, H-2', H-5', H-6', H-2'', H-5'', H-6''). 13C NMR (CDCl3, 150 MHz) 
δ 17.7 (C-20), 18.6 (C-2), 18.6 (C-11), 19.3 (C-6), 21.6 (C-19), 25.6 (C-12),  33.3 (C-4), 33.6 
(C-18), 33.7 (C-7'), 39.2 (C-7), 39.5 (C-7''), 39.6 (C-10), 40.5(C-1), 41.7(C-13), 42.1 (C-3), 43.4 
(C-8''), 43.8 (C-14), 48.5 (C-9), 49.0 (C-8), 52.2 (C-8'), 56.0 (C-5),  65.2 (C-17), 72.2 (C-9''), 
100.8 (2 OCH3O), 104.1 (C-9'), 108.1 (C-5'), 108.1 (C-5''), 109.0 (C-2''), 109.3 (C-2'), 121.4, 
(C-6''), 121.6 (C-6'), 134.3 (C-1''), 134.9 (C-1'), 137.4 (C-15), 143.2 (C-16), 145.6 (C-4''), 145.9 
(C-4'), 147.5 (C-3''), 147.6 (C-3'). 
Synthesis of (–)-9-O-[(–)-Kaur-15-en-17-oxyl]cubebin 
Dry CH2Cl2 (5 ml) was gradually added to a reaction flask with (-)-Kaur-15-en-17-ol (18) 
(10 mg, 0.035 mmol), (-)-Cubebin (13) (12 mg, 0.035 mmol) and camphorsulfonic acid (1.0 mg, 
0.0035 mmol) under Ar, after 3 days stirred in room tempeturature, then the solution was 
refluxed for another 2 days, after evaporation, the crude was purified by prepare TLC (n-Hexane: 
AcOEt= 5:1) gave an 1:1 diastereometic mixture of 9-O-[(-)-kaur-15-en-17-oxyl]cubebin (1.5 
mg, 2.4%), and recovered 13 (10.2 mg), 18 (8.2 mg). 
 
(–)-Pluviatolide (A-II). Obtained as a pale brown solid; mp 162 oC; [α]24D –43.2 (c 0.06, CHCl3); 
IR (ATR) νmax 3411, 1760 cm–1; 1H NMR (CDCl3, 400 MHz) δ 2.45-2.50 (2H, m, H-7'a, H-8'), 
2.53-2.57 (1H, m, H-8), 2.59-2.61 (1H, m, H-7'b), 2.90 (1H, dd, J = 14.0, 6.9 Hz, H-7a), 2.96 
(1H, dd, J = 14.0, 5.2 Hz, H-7b), 3.84-3.87 (1H, m, H-9'a), 3.85 (3H, s, OCH3), 4.11 (1H, dd, J = 
9.0, 7.1 Hz, H-9'b), 5.53 (1H, s, OH), 5.93-5.94 (2H, m, OCH2O ), 6.45 (1H, s, H-2'), 6.46 (1H, d, 
J = 1.9 Hz, H-6'), 6.62 (1H, dd, J = 8.3, 1.9 Hz, H-6), 6.66 (1H, d, J = 1.9 Hz, H-2), 6.69 (1H, d, 
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J = 7.7 Hz, H-5'), 6.83 (1H, d, J = 8.0 Hz, H-5); 13C NMR (CDCl3, 150 MHz) δ 34.6 (C-7), 38.3 
(C-7'), 41.0 (C-8'), 46.6 (C-8), 55.9 (OCH3), 71.2 (C-9'), 101.0 (OCH2O), 108.1 (C-5'), 108.8 
(C-2'), 111.5 (C-2), 114.2 (C-5), 122.1 (C-6), 121.5 (C-6'), 129.4 (C-1), 131.6 (C-1'), 144.5 (C-4), 
146.3 (C-3), 146.7 (C-4'), 147.9 (C-3'), 178.7 (C-9); EIMS m/z 356 [M]+ (24). 
 
Aristelegone-A (A-III). Obtained as a colorless solid; mp 156-161oC; IR (ATR) νmax 2921, 1573 
cm–1; 1H NMR (CDCl3, 400 MHz) δ 1.36 (3H, d, J= 7.0 Hz, H-9), 1.81-1.90 (1H, m, H-3a), 
2.16-2.26 (1H, m, H-3b), 2.25 (3H, s, H-10), 2.54 (1H, ddd, J= 17.4, 9.0, 4.8 Hz, H-2a), 2.74 
(1H, ddd, J= 17.4, 8.2, 4.6 Hz, H-2b), 6.69 (1H, brs, H-5), 7.85 (1H, brs, H-8); [α]D23.5=+8.3; 
EIMS m/z: 190 [M+, (51%)], 175 (25%). 
 
Cepharanone B (A-IV). Obtained as brown solid; mp 251-263 oC ; IR (ATR) νmax 1716 (C=O) 
cm–1; 1H NMR (CDCl3, 400 MHz) δ 4.09 (3H, s, OCH3), 4.13 (3H, s, OCH3), 7.10 (1H, s, H-9), 
7.59 (2H, m, H-6, H-7), 7.83 (2H, m, H-2, H-8), 9.23 (1H, m, H-5). 13C NMR (CDCl3+CD3OD, 
150 MHz) δ 57.0 (C-12), 60.6 (C-13), 105.9 (C-9), 109.6 (C-2), 121.1 (C-4a), 121.2 (C-1), 126.0 
(C-6), 127.1 (C-5a), 127.6 (C-5, C-7), 129.1 (C-8), 134.0 (C-9a), 134.8 (C-10), 151.7 (C-4), 
154.6 (C-3). HREIMS m/z: 279.0869 (cald for C17H13NO3 M+: 279.0895). 
 
(-)-Dihydrocubebin (A-V). Obtained as a pale brown solid; mp 107-110 oC; IR (ATR) νmax 3419 
cm-1, 1648 cm-1; 1H NMR (CDCl3, 400 MHz) δ 1.84 (2H, s), 2.61 (2H. dd, J= 13.7, 5.8 Hz), 2.75 
(2H. dd, J= 13.7, 8.8 Hz), 3.49 (2H. dd, J= 11.3, 3.8 Hz), 3.78 (2H. d, J= 11.3 Hz), 5.92-5.96 
(4H, m), 6.60 (2H, d, J= 7.7 Hz ), 6.64 (2H, s ), 6.71 (2H, d, J= 7.7 Hz ); [α]D25.1=-31.6; EIMS 
m/z 358 [M+, (11%)] . 
 
(-)-Haplomyrfolol (A-VI). Obtained as a amorphous solid; IR (ATR) νmax 3394, 2919, 1648, 
1509 cm-1; 1H NMR (CDCl3, 400 MHz) δ  2.57-2.80 (2H, m), 2.00 (0.4H, m), 2.15 (0.6H, m), 
2.17 (0.6H, m), 2.45 (0.4H, m), 5.23 (1H, s), 3.57 (0.4H, t, J=7.3), 3.79 (0.6H, t, J= 7.7), 3.84 
(1.2H, s), 3.87 (1.8H, s), 4.00 (0.6H, dd, J=8.4, 7.0), 4.10 (0.4H, t, J= 7.9), 5.91 (2H, m), 
6.49-6.84 (6H, m, Ar-H); [α]D23.5=-42.0; EIMS m/z 358 [M+, (10%)] . 
 
N-trans-feruloyl tyramine (A-VII). Obtained as a brown solid; mp 99-103 oC; IR (ATR) νmax 
1650 cm–1; 1H NMR (CDCl3, 400 MHz) δ 2.78 (2H, t, J= 6.8 Hz, H-7), 3.57 (2H, t, J= 6.8 Hz, 
H-8), 3.89 (3H, s, OCH3), 6.20 (1H, d, J= 15.6 Hz, H-8'), 6.79 (2H, d, J= 8.2 Hz, H-3, H-5), 6.86 
(1H, d, J= 8.2 Hz, H-5'), 6.98 (1H, brs, H-2'), 7.01 (1H, brd, J= 8.2 Hz, H-6'), 7.05 (2H, d, J= 8.2 
Hz, H-2, H-6), 7.49 (1H, d, J= 15.6 Hz, H-7'); 13C NMR (CDCl3+CD3OD, 150 MHz) δ 34.7 
(C-7), 41.0 (C-8), 55.9 (OCH3), 110.2 (C-2'), 115.2 (C-5'), 115.5 (C-3), 115.5 (C-5), 117.7 (C-8'), 
122.2 (C-6'), 127.0 (C-1'), 129.8 (C-2), 129.8 (C-6), 129.9 (C-1), 141.2 (C-7'), 147.3 (C-3'), 
148.0 (C-4'), 155.3 (C-4), 167.1 (C=O). EIMS m/z: 313 [M+, (5%)], 281 (10%), 207 (100%). 
 
9,9',-O-feruloyl-(-)-secoisolariciresinol (A-VIII). Obtained as a colorless amorphous gum; IR 
(ATR) νmax 3442, 1693 cm-1; 1H NMR (CDCl3, 400 MHz) δ 2.21 (2H, t, J= 5.8 Hz, H-8 and 8'), 
2.72 (2H, m, H-7 and 7' ), 3.77 (6H, s, 3 and 3'-OCH3), 3.92 (6H, s, 3'' and 3'''-OCH3), 4.21 (2H, 
dd, J=11.3, 5.2 Hz, H-9 and 9'), 4.38 (2H, dd, J=11.3, 8.0 Hz, H-9 and 9'), 6.28 (2H, d, J=15.7, 
H-8'' and 8'''), 6.52 (2H, s, H-2 and 2'), 6.61 (2H, d, J=8.0 Hz, H-6 and 6'), 6.80 (2H, d, J=8.0 Hz, 
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H-5 and 5'), 6.91 (2H, d, J=8.2, H-5'' and 5'''), 7.01 (2H, s, H-2'' and 2'''), 7.06 (2H, d, J=8.2, H-6'' 
and 6'''), 7.58 (2H, d, J=15.7, H-7'' and 7'''); 13C NMR (CDCl3, 150 MHz) δ131.8 (C-1 and 1'), 
111.3 (C-2 and 2'), 146.5 (C-3 and 3'), 143.9 (C-4 and 4'), 114.1 (C-5 and 5'), 121.8 (C-6 and 6'), 
35.4 (C-7 and 7'), 40.2 (C-8 and 8'), 64.6 (C-9 and 9'), 126.9 (C-1'' and 1'''), 109.5 (C-2'' and 2'''), 
146.8 (C-3'' and 3'''), 148.1 (C-4'' and 4'''), 114.7 (C-5'' and 5'''), 123.2 (C-6'' and 6'''), 145.2 (C-7'' 
and 7'''), 115.2 (C-8'' and 8'''), 56.1 (3 and 3'-OCH3), 55.7 (3'' and 3'''-OCH3), 167.4 (C-9'' and 9'''); 
FABMS m/z: 715 [M+H]+. 
 
Magnoflorine (V-IX). Obtained as brown solid; mp 251-263 oC; IR (ATR) νmax 3332 cm-1; 1H 
NMR (CD3OD, 400 MHz) δ 2.35 (1H, t, J=12.9, H-7), 2.51 (1H, d, J=17.3, H-4), 2.70 (3H, s, 
NCH3), 2.85 (1H, d, J= 12.4 Hz, H-7), 3.02 (1H, m, H-4), 3.14 (3H, s, NCH3), 3.37 (2H, m, H-5), 
3.66 (3H, s, OCH3) 3.72 (3H, s, OCH3), 3.75 (1H, m, H-6a), 6.37 (1H, s, H-3), 6.38 (1H, d, J= 
7.2 Hz, H-8), 6.57 (1H, d, J=8.0 Hz, H-9); 13C NMR (CD3OD, 150 MHz) δ 24.7 (C-4), 31.7 
(C-7), 43.6 (C-14), 54.0 (C-15), 56.4 (C-12), 56.4 (C-13), 62.4 (C-5), 71.2 (C-6a), 109.6 (C-3), 
110.8 (C-9), 115.8 (C-3a), 117.0 (C-8), 121.1 (C-11c), 123.6 (C-11b), 123.7 (C-11a), 126.1 
(C-7a), 150.0 (C-11), 150.9 (C-1), 151.8 (C-10), 153.2 (C-2); EIMS m/z: 342 [M+, (24%)]. 
 
(–)-Cubebin (13). Obtained as yellow prisms; mp 123–124 oC; [α]21D –51.8 (c 0.86, CHCl3); IR 
(ATR) νmax 3346 cm–1; 1H and 13C NMR, see Tables 5 and 6, respectively; EIMS m/z: 356 [M+, 
(36%)]. 
 
(–)-Hinokinin (14). Obtained as a yellow gum; [α]22D –31.1 (c 0.65, CHCl3); IR (ATR) νmax 1767 
cm–1; 1H NMR (CDCl3, 400 MHz) δ 2.44-2.49 (2H, m, H-8', H-7'a), 2.51-2.59 (2H, m, H-8, 
H-7'b), 2.84 (1H, dd, J = 14.0, 7.2 Hz, H-7a), 2.98 (1H, dd, J = 14.0, 5.2 Hz, H-7b), 3.86 (1H, dd, 
J = 9.4, 7.6 Hz, H-9'a), 4.13 (1H, dd, J = 9.4, 6.8 Hz, H-9'b), 5.93-5.94 (4H, m, OCH2O), 
6.45-6.49 (2H, m, H-6 or H-6', H-2), 6.60 (1H, dd, J = 8.0, 1.6 Hz, H-6 or H-6'), 6.63 (1H, d, J = 
1.6 Hz, H-2'), 6.70 (1H, d, J = 8.0 Hz, H-5), 6.73 (1H, d, J = 7.6 Hz, H-5'); 13C NMR (CDCl3, 
100 MHz) δ 34.8 (C-7), 38.3 (C-7'), 41.3 (C-8'), 46.4 (C-8), 71.1 (C-9'), 100.97 (OCH2O), 
100.98 (OCH2O), 108.2 (C-5), 108.3 (C-5'), 108.8 (C-2), 109.4 (C-5'), 121.5 (C-6), 122.2 (C-6'), 
131.3 (C-1'), 131.6 (C-1), 146.3 (C-4 or C-4'), 146.4 (C-4 or C-4'), 147.8 (C-3 or C-3'), 147.9 
(C-3 or C-3'), 178.4 (C-9); EIMS m/z 355 [M+H +, (9%)]. 
 
(–)-Kaur-16-en-19-oic acid (17). Obtained as colorless prisms; mp 164 oC; [α]23D –99.6 (c 0.65, 
CHCl3); IR (ATR) νmax 1689 cm–1; 1H NMR (CDCl3, 400 MHz) δ 0.81 (1H, dt, J = 13.6, 4.0 Hz, 
H-1a), 0.95 (3H, s, H-20), 1.01 (1H, dt, J = 13.2, 4.4 Hz, H-3a), 1.03-1.09 (2H, m, H-5, H-9), 
1.14 (1H, dd, J = 11.2, 4.8 Hz, H-14a), 1.24 (3H, s, H-18), 1.41-1.62 (7H, m, H-2, H-7, H-11a, 
H-12), 1.80-1.90 (4H, m, H-1b, H-6, H-11b), 1.99 (1H, d, J = 10.0 Hz, H-14b), 2.04-2.06 (2H, m, 
H-15), 2.16 (1H, d, J = 14.4 Hz, H-3b), 2.64 (1H, br s, H-13), 4.74 (1H, br s, H-17a), 4.80 (1H, 
br s, H-17b); 13C NMR (CDCl3, 100 MHz) δ 15.6 (C-20), 18.4 (C-11), 19.1 (C-2), 21.8 (C-6), 
29.0 (C-18), 33.1 (C-12), 37.8 (C-3), 39.7 (C-10), 39.7 (C-14), 40.7 (C-1), 41.3 (C-7), 43.7 (C-4), 
43.8 (C-13), 44.2 (C-8), 49.0 (C-15), 55.1 (C-9), 57.1 (C-5), 103.0 (C-17), 155.9 (C-16), 184.5 
(C-19); EIMS m/z 303 [M+H +, (24%)]. 
 
(–)-Kaur-15-en-17-ol (18). Obtained as pale brown prisms; mp 128–131 oC; [α]23D –24.8 (c 0.40, 
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CHCl3); IR (ATR) νmax 3324 cm–1; 1H and 13C NMR, see Tables 5 and 6, respectively; EIMS m/z: 
289 [M+H +, (25%)]. 
 
Smooth Muscle Contraction Test Using Guinea-pig Ileum. Male albino guinea pigs weighing 
300–450 g were used for all experiments. Contraction of smooth muscle was measured in ileal 
preparation as described previously.30 The isolated ileum was placed in Krebs–Henseleit solution 
(mM): NaCl, 112.8; NaHCO3, 25.00; glucose, 11.49; KCl, 5.90; CaCl2, 1.97; NaH2PO4, 1.22, 
and MgCl2, 1.18. The ileum was set up under 1 g tension in a 10 mL organ bath containing the 
nutrient solution. The bath was maintained at 38.5 ºC and continuously bubbled with a gas 
mixture of 95% O2 and 5% CO2. After a 0.5 h equilibration period, the ileum was stimulated 
with a maximum response to ACh (3 μM, three times) to check its suitability. Contractions were 
isotonically recorded using an isotonic transducer (TD-112S, Nihon Koden, Tokyo, Japan), a 
balancing box (JD-112S, Nihon Koden, Tokyo, Japan) and a Powerlab system (AD Instruments, 
Castle Hill, Australia). After stable control contraction by ACh (3 μM), the isolated ileum was 
transmurally stimulated by platinum needle-ring electrodes using square wave pulses of 
supramaximal voltage (38.6 V, monophasic pulses 0.2 Hz for 0.3 ms pulse duration) using a 
stimulator (SEN-3301, Nihon Koden, Tokyo, Japan) and a DC strain amplifier (SEG 3104, 
Nihon Koden, Tokyo, Japan). The experiments on ECI were performed after a stable twitch 
contraction was obtained by electrical stimulation in the absence of samples. The ileal responses 
were observed by cumulatively increased concentration of the samples (0.03 and 0.1 mg/mL for 
extracts, 10, 30, 100 μM for compounds). On the other hand, the experiments on AChI were 
conducted in the presence of each concentration (a noncumulative manner) of samples (0.03 and 
0.1mg/mL for extracts, 10, 30, 100 μM for compounds) after at least three stable contractions 
induced by ACh (3 μM). Samples were added 20 min before the addition of ACh. The height of 
the contraction induced by ACh was measured in the absence and the presence of samples. 
Contraction (%) was determined by dividing the contractile height under the sample-treated 
condition by that under the nontreated condition. The extract and the isolated pure compounds 
were dissolved in dimethyl sulfoxide. Stock solutions were stored at –4 ºC, and a fresh dilution 
was performed daily in the nutrient solution. The final concentration of dimethyl sulfoxide was 
less than 1%.  All data are shown as the mean ± S.E.M. of results obtained from four to five 
animals. Statistical analyses were performed with a two-tailed paired t-test for paired 
observations of two groups. A P value < 0.05 was considered statistically significant. 
 
Brine Shrimp Bioassay. 
The bioassay was carried out according to essentially the same literature procedure. A half spoon 
of brine shrimp eggs (Nihon Animal Pharmaceutical Inc., Tokyo, Japan) were hatched in a 
container filled with air-bubbled artificial sea water which was prepared with 10g of a 
commercial salt mixture (GEX Inc., Osaka, Japan) and 500 ml of distilled water. After 48 h, the 
phototropic shrimps were collected by pipette for bioassay. Ten shrimps were transferred to each 
vial, and artificial water was added to make 5 ml. to this vial each sample which was dissolved in 
0.025 ml of DMSO was regarded as a control. The surviving shrimps were counted 
microscopically in the stem of the pipette against a lightened background after 24h, the percent 
deaths at each dose was counted as the following formula: %deaths=(the number of death 
shrimps-the number of half death shrimps×0.7 )/10×100. 
 MPLC n-Hexane: AcOEt 10:1→MeOH 
Then PTLC hexane: Et2O= 10:1 
PTLC hexane: Et2O=10:1 
9-O- [(-)-Kaur-15-en-17-oxyl]cubebin (A-I) 
(2.8 mg)
PTLC n-Hexane: AcOEt=15:1
CC. n-Hexane: AcOEt=10:1→5:1→1:1→0:1→MeOH
CC.  n-Hexane: AcOEt=20:1→10:1→5:1→0:1→Acetone→MeOH
recrystallized by n-Hexane MPLC n-Hexane: AcOEt=8:1→MeOH
Then PTLC n-Hexane: Et2O=10:1 
MPLC n-Hexane: AcOEt
12:1→MeOH 
 washed by Et2O Fil. 
A part (6.9819 g) washed by n-Hexane 
Extraction by  Soxhlet  apparatus 
n-Hexane ext.8.4344g (2.04%) CHCl3 ext. 7.8318g (1.90%) EtOH ext. 61.01 g (14.8%)
Fr. A 2.7073g Fr.B 2.4425g Fr.C 1.5636g 
Aristolochia constricta（412.93g） 
Fr.5  716.9 mg 
Fr.2  250.0 mg Fr.3  138.0 mg Fr.4  101.1 mg Fr.7.  65.5 mg 
Fr.2.  19.0 mg 
(-)-Kaur-16-en-19-oic acid (8)
(164.7 mg) 
Fr.6  472.5 mg 
MPLC  n-Hexane: Et2O=5:1→1:1→Acetone
(-)-Kaur-15-en-17-ol (18)
      (63.5 mg) 
(-)-Kaur-15-en-17-ol (18)
      (4.0 mg) 
9-O-methylcubebin
     (2.6 mg) 
9-O- [(-)-Kaur-15-en-17-oxyl]cubebin (A-I)
(2.3 mg) 
ppt. 
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PTLC cyclohexane: AcOEt=5:1 
recrystallized by  
n-Hexane and Et2O
CC Benzene: Et2O 
10:1→5:1→0:1→MeOH 
Extraction by Soxhlet apparatus 
(+)-4,7-Dimethyl-6-methox
y-1-tetralone (15) (12.9 mg)
PTLC  n-Hexane: Acetone=3:1 
N-trans-teruloyl tyramine (A-VII) 
CC   CHCl3: Acetone 
5:1→3:1→1:1→0:1→MeOH 
Aristololactam A II
     (5.9 mg) 
recrystallized by Acetone
CC Benzene: AcOEt 
5:1→2:1→1:1→0:1→MeO
recrystallized by Et2O and MeOH 
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 (-)-Dihydrocubebin (A-V) (-)-Haplomyrfolol (A-VI) 
PTLC  n-Hexane: Acetone=2:1
CC  
CHCl3: AcOEt=5:1→0:1→MeOH 
MPLC  CHCl3: AcOEt=5:1→2:1→0:1→MeOH
recrystallized by n-Hexane and Et2O 
recrystallized by Et2O and MeOH 
(-)-Pluviatolide (A-II) 
CC.  n-Hexane: AcOEt=5:1→2:1→0:1→MeOH 
recrystallized by 
Et2O and MeOH 
recrysted by  
n-Hexane and Et2O 
(-)-Kaur-15-en-17-ol (18)
       (22.4 mg) 
(-)-Hinokinin (14) 
recrystallized by  
n-Hexane and Et2O
recrystallized by n-Hexane 
CC.  n-Hexane: AcOEt=10:1→5:1→0:1→MeOH 
Washed by Et2O 
CC.  Benzene: Et2O=10:1→5:1→1:1→0:1→MeOH 
fil. 
A part (6.9819 g) washed by n-Hexane 
n-Hexane ext.8.4344g (2.04%) CHCl3 ext. 7.8318g (1.90%) EtOH ext. 61.01 g (14.8%) 
Fr. A 2.7073g 
Fr.B 2.4425g Fr.C 1.5636g 
Fr.4  122.9 mg 
Aristolochia constricta（412.93g） 
Fr.8  42.4 mg Fr.5  57.7 mg Fr.9  76.7 mg Fr.10  382.3 mg Fr.6  131.2 mg Fr.13  302.3 mg Fr.14  63.4 mg 
Fr.2  48.1 mg Fr.3  18.1 mg 
SS02196A-3 
Fr.6 25.8 mg 
SS02196A-6 
(-)-Kaur-16-en-19-oic 
acid (17) (15.3 mg) 
MPLC  Benzene: Et2O=5:1→0:1→MeOH 
recrystallized by n-Hexane 
Fr.3  4.8 mg Fr.5  4.4 mg 
Fil.  0.8 mg 
CC Benzene: Et2O 
10:1→5:1→0:1→MeOH 
Fr.4  11.3 mg Fr.5. 14.8 mg
fil.  5.7 mg
ppt.(5.3 mg)
(-)-Pluviatolide
(A-II)
ppt. (160.8 mg)
(-)-Cubebin (13)
fil. 118.2 mg 
fil.. 295.5 mgppt..  6.3 mg
Fr.2. 16.0 mg
Fr.4 7.1 mg 
(-)-Cubebin 
(13) 
Fr.5  2.9 mg Fr.8  4.5 mg 
Fr.5 93.6 mg
Cepharanone B (A-IV)
fil..  97.5 mg 
ppt.  5.2 mg
Fr.3. 44.9 mg Fr.4. 6.1 mg
Fr.4. 8.0 mg Fr.5..11.4 mg 
Fr.3. 30.0 mg
recrystallized by Et2O and MeOH 
Fr.15  101.1 mg Fr.16  588.8 mg
fil.  606.0 mg 
CC  CHCl3: Acetone=5:1→2:1→1:1→0:1→MeOH 
Fr.3. 66.0 mg Fr.4..75.9 mg
recrystallized by MeOH 
Fr.5..21.5 mg
Fr.2..6.7 mg 
ppt. 
(+)-4,7-Dimethyl-6-methox
y-1-tetralone (15) 
Aristelegone-A (A-III)
     (1.6 mg) 
(-)-Kaurane-16α,17-diol (18)
         (22.1 mg) 
(-)-Kaurane-16α,17-diol (18)
         (39.3 mg) 
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recrystallized by MeOH
recrystallized by MeOH
A part (6.9819 g) washed by n-Hexane 
PTLC  CHCl3: MeOH=10:1
β-Sitosterol glycoside
recrystallized by Acetone 
N-trans-teruloyl tyramine (A-VII)
PTLC Benzene: Acetone=4:1
Aristololactam A II 
    (4.3 mg) 
MPLC CHCl3: Acetone = 
8:1→3:1→1:1→MeOH 
Aristolochic acid-1
    (15.1 mg) 
washed by MeOH
CC    CHCl3: Acetone 
3:1→2:1→1:1→0:1→MeOH 
CC.  CHCl3: Acetone=5:1→1:1→0:1→MeOH Aristolochic acid-1
   (433.2 mg)
washed by Et2O 
fil. 
extracted by  Soxhlet  apparatus 
n-Hexane ext.8.4344g (2.04%) CHCl3 ext. 7.8318g (1.90%) EtOH ext. 61.01 g (14.8%)
Fr. A 2.7073g Fr.B 2.4425g Fr.C 1.5636g 
Aristolochia constricta（412.93g） 
PPt.  602.1 mg 
Fr.6  33.0 mg Fr.10  83.8 mg Fr.12  244.7 mg 
Fr.3.   24.1mg 
Fr.6   45.5 mg 
Fil.  837.4 mg 
recrystallized by MeOH 
MPLC CHCl3: Acetone=
5:1→1:1→0:1→MeOH 
Fr.11  66.7 mg 
Fr.3.  36.8mg 
Fr.2  16.0 mg 
ppt.  3.6 mg 
GZ01154A-2 
recrystallized by MeOH
Fr.13  55.3 mg 
PPt.  2.7 mg 
GZ01080A-2 
PPt.. 2.7 mg
GZ01089A-2 
GZ01154A-3
GZ02022A-2-1
  4.7 mg 
Fr.2  4.5  mg 
EtOH ext
61.01 g 
ppt. 
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Chapter 1. Introduction 
 
In recent ten years, organocatalysts as a new branch of enantioselective synthesis have 
been widely developed. They are defined as small organic molecules which catalyze organic 
reactions.1 Many chemists have devoted to design new organocatalyst based on proline, 
thioureas, quinidines, guanidines, and so on, to solve important problems in chemical synthesis. 
Organocatalysts bring potential advantages for savings in cost, time and energy, an easier 
experimental procedure, which is no need for special reaction vessels, storage containers, and 
experimental techniques. Small organic molecules are environmentally friendly and could 
reduce chemical waste. An effective solution to a great number of important asymmetric 
synthesis and new enantioselective reactions provided by organocatalysts are yet to come. 
     
 
Chapter 2 Survey of Guanidines-Catalyzed Asymmetric Reaction 
Guanidines can be classified as organic bases such as amines and amidines (Figure 1), 
regarded as one of strong bases due to resonance stabilizability of their conjugated acids, and 
actually act as base catalysts in variety of organic synthesis.2 Some of the typical guanidines 
are tetramethylguanidine, and pentaalkylguanidines like tert-butyltetramethylguanidine which 
are known as Barton’s bases.2a The presence of three nitrogen atoms in the guanidine 
compounds may lead to wide and easy molecular modification, as it is theoretically possible to 
introduce five chiral centers at the nitrogen atoms. Depending on the structural feature around 
the guanidine nitrogen atoms, chiral guanidine could be classified into six groups: (I) acyclic, 
(II) monocyclic, (III) bicyclic, (IV) polycyclic，(V) bisguanidinium salt and (VI) an axially 
chiral binaphthyl backbone guanidine.  
 
               Figure 1. Examples of organic base. 
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2.1 Chiral Acyclic Guanidine 
Typical examples of reported chiral acyclic guanidines are shown in Figure 2. 
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Figure 2 Chiral Acyclic Guanidines. 
 
In 1996, Lipton3 and co-workers reported that a cyclic dipeptide 1 catalyzed asymmetric 
Strecker reaction of substituted imines to α-amino nitriles. The products were obtained 
generally in high enantiomeric excess, which the aliphatic examples afforded low selectivity 
(Scheme 1). 
 
Scheme 1. Asymmetric Strecker reactions of N-benzhydryl imines catalyzed by dipeptide 1. 
 46
 
Henry reaction of nitroalkane and aldehydes catalyzed by guanidines was investigated by 
Ma,4 in which guanidine 2a was found to be most effective (Scheme 2) and the 
enantioselectivity was up to 92% when aldehyde with R = iPr was applied. 
 
Scheme 2. Diastereoselective Henry reaction catalyzed by guanidine 2a. 
 
The same group described the utilization of chiral acyclic guanidines as a catalyst of 
Michael addition of glycine derivatives to acrylic esters and Diels-Alder reaction between 
anthrone and maleimide. The addition products were generated with low enantioselectivity. 
Although the enantioselectivity was poor, these results demonstrate the ability of chiral 
guanidines as asymmetric catalysts in the Michael addition5 (Scheme 3) and Diels-Alder 
reaction6 (Scheme 4). 
 
Scheme 3. Asymmetric conjugate additions of glycinate to ethyl acrylate. 
 
 
Scheme 4. Diels-Alder reaction of anthrone and maleimide. 
 
 
 
Nagasawa et al. developed Henry reaction (Schemes 5-6) with aldehydes and nitroalkanes 
catalyzed by guanidine-thiourea bifunctional oragnocatalyst 5 in high diastereo- and 
enantioselectivity.7 It was proposed that the thiourea moiety and the guanidine part of 5 interact 
strongly with the carbonyl group and nitronate anion, respectively. The proposed transition 
structure was shown in Scheme 7, in which the aldehyde (R group) favors an anti conformer to 
nitronate rather than a gauche position. 
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Scheme 5. Asymmetric Henry reactions of various aldehydes and nitroalkanes catalyzed by guanidine–
thiourea 5. 
 
 
Scheme 6. Diastereoselective Henry reaction catalyzed by guanidine–thiourea 5. 
 
 
Scheme 7. Proposed transition state of the guanidine-thiourea bifunctional compound-catalyzed Henry 
reaction. 
     
Designed acyclic hydroxyl-guanidine 6 was used to catalyze the epoxidation of 
chalcones,8 the hydroxyl group of which was used as a hydrogen-bond donor was crucial for 
asymmetric induction. Enantioselectivity was lost once the group was protected with a methyl 
group (Scheme 8). 
 
Scheme 8. Asymmetric nucleophilic epoxidation reactions of various chalcones catalyzed by acyclic 
hydroxy–guanidine 6. 
 
 48
 
Jacobsen et al. reported enantioselective Claisen rearrangements catalyzed by 
guanidinium salt 7 with hydrogen-bond donors towards ether oxygen.9 X-ray structural 
analysis of 7 reveals a guanidinium functionality disposed in a pseudo-C2-symmetric 
conformation with two s-cis C-N bonds (Scheme 9). 
 
Scheme 9. Enantioselective Claisen rearrangement reactions catalyzed by guanidinium salt 7. 
 
 
Tsogoeva et al. tested tripeptides 8 including argimine residue as catalysts for the 
conjugate addition reaction of 2-nitropropane and 2-cyclohexen-1-one (Scheme 10). Low 
conversion was observed in a nonpolar solvent such as CHCl3, while moderate ee (69%) was 
achieved in CHCl3/DMSO.10
 
Scheme 10. Michael reactions of 2-nitropropane to 2-cyclohexene-1-one catalyzed by tripeptides 8a-b. 
 
 
Linton et al. reported a peptide-catalyzed Michael reaction of nitroalkanes and methyl 
vinyl ketone (Scheme 11), in which moderate enantioselectivity was observed.11 Further 
mechanistic ananlysis suggested hydrogen-bonding interactions between the peptide and 
anionic intermediate. 
 
 
Scheme 11. Enantioselective Michael reactions of various α-nitroketones to methyl vinyl ketone 
catalyzed by pentapeptide 9. 
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 2.2 Chiral Monocyclic Guanidine 
    Typical examples of reported chiral monocyclic guanidines are shown in Figure 3. 
 
 
   Figure 3. Chiral monocyclic guanidines 
 
Kobayashi et al. developed enantioselective Mannich-type reactions of fluorenone imine 
derivatives of glycine esters catalyzed by guanidine ent-11a designed by our group.12 Notably, 
the fluorenone imines are much more reactive than corresponding benzophenone imines. It’s 
believed the fluorenone imines are stabilized by resonance involving the 14π electrons of the 
aromatic fluorene moiety (Scheme 12). 
 
Scheme 12. Enantioselective Mannich reactions of various N-Boc protected imines catalyzed by 
guanidine ent-11a. 
 
 
 
Taylor et al. 13 designed chiral guanidines 13 derived from chiral primary aminoalcohol 
which demonstrated to mediate the epoxidation of chalcone and cyclic enones (Scheme 13).  
 
Scheme 13. Guanidine 13-mediated asymmetric epoxidation of chalcone. 
 
 
A bifunctional guanidine 14 was found to promote the asymmetric 1,4-addition 
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ofβ-ketoesters to nitroolefins with dual activation in one molecule.14 It was discovered with 
X-ray diffraction analysis of a single crystal of 14 that the guanidine formed two H-bonds, one 
intramolecularly and the other intermolecularly (Scheme 14). A preliminary mechanism for this 
direct nitro-Michael reaction of cyclic β-ketoesters has been proposed to illustrate the dual 
activation mode. 
 
Scheme 14. Enantioselective Michael reactions of β-ketoesters with nitroolefins catalyzed by 
bifunctional guanidine 14 via an amino amide skeleton. 
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2.3 Chiral Bicyclic Guanidines 
    Typical examples of reported chiral bicyclic guanidines are shown in Figure 4. 
 
      
     Figure 4. Chiral Bicyclic Guanidines 
 
In 1999, Corey et al.15 reported a novel catalytic enantioselective Strecker reaction which 
utilizes the C2-symmetric bicyclic guanidine 15e as a bifunctional catalyst for the addition of 
HCN to achiral N-benzhydrylimines (Scheme 15). Modeling of the imine hydrogen bond to the 
guanidinium in pre-transition state assembly indicates the possibility of a three-dimensional 
arrangement depicted in Scheme 16, where the cyanide is positioned to attack the re face of the 
imine carbon, a trajectory that leads to the predomination of enantiomer with R configuration. 
A proximal phenyl group of the catalyst can undergo π-stacking with one of the benzhydryl 
phenyls, while the si face of the imine carbon is blocked by the other phenyl of the benzhydryl 
group. At the same time the aryl group π-conjugated to the imine is accommodated in a vacant 
quadrant of the guanidine face and can experience van der Waals interaction with the guanidine 
core and distal phenyl edge of catalyst 15e. Rotation of imine by 180o about the H-N bond to 
expose the si face removes the van der Waals attractions and generates steric repulsion between 
the π-conjugated aldimine aryl and the proximal phenyl of catalyst 15e. 
 
 
Scheme 15. Catalytic enantioselective Strecker reaction by 15e. 
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 Scheme 16. Pre-transition states for the Strecker reactions catalyzed by 15e. 
 
Tan et al.16 reported Diels-Alder reactions of substituted anthrones and maleimides 
catalyzed by the chiral bicyclic guanidine 15a (Scheme 17). When dithranol was applied to this 
reaction instead of anthrones, only Michael adducts was obtained (Scheme 18). 
 
Scheme 17. Chiral bicyclic guanidine-catalyzed Diels-Alder reactions between substituted anthrones and 
maleimides. 
        
Scheme 18. Enantioselective Michael reactions of dithranol to various maleimides and activated olefins 
catalyzed by bicyclic guanidine 15a. 
 
 
The Michael reaction of nitroalkanes to chalcone was investigated with catalysts 15a-d 
(Scheme 19) and better ee was obtained in the reaction with guanidines carrying bulkier 
appendages.17
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Scheme 19. Screening of bicyclic guanidine catalysts 15a-c for Michael reactions of nitroalkanes to 
chalcone. 
 
The same group utilized guanidine 15c for catalytic enantioselective Michael addition 
reactions between various 1,3-dicarbonyl compounds and 2-cyclopenten-1-one, maleimide and 
trans-4-oxo-4-arylbutenoates, in which a highly enantioselective Michael adducts was obtained 
(Scheme 20).18
 
Scheme 20. Bicyclic guanidine 15c catalyzed Michael additions of various 1,3-dicarbonyl compounds to 
2-cyclopenten-1-one, maleimide and trans-4-oxo-4-arylbutenoates. 
 
 
 
 
 
The direct addition of P(O)-H bonds (dialkyl phosphates or dialkyl phosphine oxides 
[R2P(O)H]) across activated alkenes is one of the most convenient routes to generate P-C 
bonds. Tan et al. have discovered bicyclic guanidine 15c was effective in catalyzing 
asymmetric phospha-Michael reaction between diaryl phosphine oxide and nitroalkenes.19 This 
is a direct and atom economical method to synthesize chiral α–substituted β-phosphine 
oxides and β–aminophosphines (Scheme 21). 
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Scheme 21. Bicyclic guanidine 15c catalyzed phospha-Michael additions of various diaryl phosphine 
oxides to conjugated aryl nitroalkenes. 
 
 
Enantioselective protonation of enolates is a conceptually simple and efficient approach to 
the preparation of chiral carbonyl compounds withα-stereogenic center. A tandem process 
involving a conjugate addition followed by a highly enantioselective protonation or deuteration 
can be catalyzed by the bicyclic guanidine 15c (Scheme 22).20  
 
Scheme 22. Enantioselective protonations of 2-phthalimidoacrylate and itaconimide catalyzed by 
bicyclic guanidine 15c. 
 
 
 
The Brønsted base catalyzed 1,3-proton shift reaction, proceeding through deprotonation 
and protonation sequences, allows allenes to be prepared directly from alkynes. Tan et al.21 
found that guanidine 15c was demonstrated to be a good catalyst for enantioselective 
isomerization of alkynes (Scheme 23). 
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Scheme 23. Enantioselective Isomerization of 4-Ary 3-Alkynoate 
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Trans-amination reaction of an imine was catalyzed by guanidine 15e (Scheme 24), in 
which modest ee value was obtained with various imines.22
 
Scheme 24. Enantioselective transamination reactions of an imine catalyzed by bicyclic guanidine 15e. 
 
 
A range of structurally and functionally variant enantiopure cyclic guanidines have been 
prepared by Taylor et al,23 and the attempt to catalyze the enantioselective epoxidation was 
showed in Scheme 25. The best enantiomeric excess was observed with using guanidine 13. 
 
Scheme 25. Asymmetric epoxidation of amidoquinone mediated by various guanidines. 
 
 
 
Basavaiah et al. reported that guanidine 17 catalyzed the borane-mediated reduction of 
phenacyl bromide,24 in which 37 % ee was achieved (Scheme 26). 
 
Scheme 26. Chiral guanidine 17 catalyzed borane reduction of phenacyl bromide. 
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 2.4 Polycyclic Guanidinium Salts 
Typical examples of reported chiral polycyclic guanidinium salts are shown in Figure 5. 
 
 
         Figure 5. Chiral Polycyclic Guanidinium Salts 
 
C2-symmetric guanidinium salts 18 were synthesized to investigate the nitro-aldol (Henry 
reaction) and nitro-Michael reactions.25 The free base of 18a catalyzed the reaction of 
isovaleraldehyde with nitromethane and enantioselectivity of 20% ee was observed (Scheme 
27). Similarly the same guanidine catalyzed asymmetric Michael reactions of nitroalkanes in 
70% yield and with 23% ee (Scheme 28).  
 
Scheme 27. Guanidine catalyzed asymmetric Henry reactions. 
 
 
 
Scheme 28. Guanidine catalyzed asymmetric Michael reactions of nitroalkanes. 
 
 
 
A series of robust guanidinium salts 18 were screened for phase-transfer asymmetric 
epoxidation of chalcone (Scheme 29) and alkylation of glycinate (Scheme 30). Chiral 
guanidine 18a was found to be an excellent catalyst for the epoxidation. Enantioselectivity was 
up to 93% ee.26
 
Scheme 29. Guanidinium salt 18a catalyzed phase-transfer asymmetric epoxidation of chalcone. 
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Scheme 30. Guanidinium salt 18a catalyzed phase-transfer alkylation of glycinate. 
 
 
 
Nagasawa et al. 27 reported a novel C2-symmetric chiral cyclic guanidinium salt 19 as 
alkylation reaction catalysts (Scheme 31). The phase-transfer catalyst guanidinium salt 19 was 
considered to generate the corresponding guanidium salt in aqueous potassium hydroxide, and 
then forms a complex with the Z-enolate of Schiff base through ionic and hydrogen-bonding 
interactions. The electrophile approaches from the less hindered face of this complex to give 
the alkylation product (Scheme 32). 
 
Scheme 31. Asymmetric alkylation reactions of glycinate with various alkyl halides catalyzed by 
pentacyclic guanidinium salt 19. 
 
 
 
Scheme 32. Proposed mechanism of pentacyclic guanidine-catalyzed alkylation. 
 
 
Guanidium salts 19 and 20 also catalyze the phase-transfer epoxidation of chalcones.28 
Moderate ee values were obtained with various chalcones (Scheme 33). 
 
Scheme 33. Asymmetric nucleophilic epoxidation reactions of various chalcones with pentacyclic 
guanidinium salts 19 and 20. 
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2.5 Chiral Bisguanidinium salt 
  Typical examples of reported chiral bisguanidium salt are shown in Figure 6. 
 
       Figure 6. Chiral bisguanidinum salt. 
 
Recently, Tan et al. found bisguanidinium salt 21 catalyzes phospha-Mannich reaction of 
the secondary phosphine oxide and imine.29 Guanidinium salt with different molar ratio of acid 
part per guanidine carried out a different enantioselectivities (Table 1, entries 1-5), the highest 
ee was obtaind with catalyst 21· HBF4 (entry 3). Catalysts with different counterions were also 
tested (entries 6, 8). The optimum conditions were found with using 21· HBArF4, in which 92% 
ee vaule was obtained (entry 8). Continuously, they investigated various imines and phosphine, 
and a series of enantiomerically enriched α-amino phosphine oxides and α-aminophosphinates 
were prepared (Scheme 34). 
 
Table 1. Guanidine- and guanidinium-catalyzed phospha-Mannich reactions. 
 
 
Scheme 34. Guanidinium-catalyzed phospha-Mannich reaction of phosphine oxides and imines. 
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2.6 Axially Chiral Binaphthyl Backbone-Incorporated Guanidines 
Typical examples of reported axially chiral binaphthyl backbone-incorporated guanidines 
are shown in Figure 7. 
 
Figure 7. Axially chiral binaphthyl backbone-incorporated guanidine. 
 
Terada et al.30 developed a new strategy for designing chiral guanidine molecules as 
efficient organocatalysts, which features the introduction of an axially chiral binaphthyl 
backbone. They investigated the 1,4-addition of 1,3-dicarbonyl compounds to conjugated 
nitroalkenes, and the novel axially chiral guanidine 22a was proved as highly active and 
enantioselective organocatalyst for the 1,4-addition reactions (Scheme 35).  
The same group also demonstrated the highly enantioselective 1,4-addition reaction of 
nitroalkenes with diphenyl phosphate catalyzed by a axially chiral guanidine 22b (Scheme 
36).31
 
Scheme 35. Asymmetric Michael reactions of various 1,3-dicarbonyl compounds with conjugated 
nitroalkenes catalyzed by guanidine 22a. 
 
 
Scheme 36. Asymmetric phospha-Michael reactions of diphenyl phosphate with conjugated nitroalkenes 
catalyzed by guanidine 22b. 
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In their continued efforts to develop efficient chiral guanidine catalysts, they designed a 
new type of axially chiral guanidine 23 with a seven-membered-ring structure32, other than the 
nine-membered-ring structure guanidine (22a and 22b). Two bonding modes of the ion pairs 
through multi-hydrogen-bonding interactions were illustrated between oxygen atoms of 
substrates and the N-H protons of guanidinium ion 23’with C2 symmetry. And the bulky 
aromatic substituents group Ar arranged with C2 symmetry would enmerge an efficient chiralty 
environment (Figure 8). They also reported the electrophilic amination of unsymmetrically 
substituted 1,3-dicarbonyl compound in a high enantioselectivity (Scheme 37). 
 
 
Figure 8. Two binding modes of the ion pairs derived from 23' with enolate form. 
 
 
Scheme 37. Asymmetric electrophilic amination reactions of various 1,3-dicarbonyl compounds. 
 
 
Guanidine 23 can accept an acidic proton to generate a guanidinium ion. This cationic ion 
having an acidic proton can also play a role of acid catalyst (Scheme 38). It was demonstrated 
that [3+2]-cycloaddition reaction of various Schiff bases with dimethyl maleate catalyzed by 
guanidine 23 yielded the corresponding pyrrolidine derivatives in good enantioselectivity.33 
The possible reaction mechanism was explained through a precursor of azomethine ylides 
(Scheme 39). 
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Scheme 38. [3+2]-Cycloaddition reaction of various Schiff bases with malonate catalyzed by (R)-25. 
 
Scheme 39. Plausible reaction mechanisms of enantioselective [3+2]-cycloaddition reaction catalyzed by 
axially chiral guanidine 23. 
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2.7 Chiral Guanidine Developed by Our Group 
 
2.7.1 Alkylative esterification 
One of the most general methods for the preparation of esters is acylation of alcohols. In 
1998, Isobe et al.34 reported the first application to the asymmetric alkylative esterification of 
benzoic acid with racemic (1-bromoethyl)benzene using chiral monocyclic guanidine 12a as a 
chiral base (Scheme 40). 
 
Scheme 40. Kinetic resolution through alkylative estrification mediated by chiral guanidine. 
           
 
2.7.2 Nucleophilic epoxidation 
Effective asymmetric epoxidation was observed when chalcone was treatd with bulky 
cumene hydroperoxide in toluene in the presence of monocyclic guanidine 12b to give an 
epoxide in 90% yield and with 70% ee (Scheme 41).35
 
Scheme 41. Guanidine 12b catalyzed epoxidation of chalcone. 
 
 
2.7.3 Asymmetric silylation of secondary alcohols 
In 2001, Isobe et al. developed the first example of asymmetric silylation of secondary 
alcohols mediated by chiral guanidines.36 Reactions of racemic indan-1-ol and 
chlorotriisopropylsilane (TIPSCl) in the presence of bicyclic guanidine 15h gave a good ee, up 
to 70% (Scheme 42). 
 
Scheme 42. Bicyclic guanidine 15h mediated kinetic resolution of secondary alcohols through 
asymmetric silylation. 
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 2.7.4 Azidation 
Treatment of indan-1-ol with diphenylphosphoryl azide in dichloromethane at room 
temperature in the presence of a C2-symmetric bicyclic guanidine 15c, gave 1-azidoindan in 
60% chemical yield with 30% ee (Scheme 43).35
 
Scheme 43. Bicyclic guanidine 15g mediated kinetic resolution of 1-indanol through asymmetric 
azidation. 
 
    
2.7.5 Trimethylsilyl (TMS) cyanation 
Application of modified guanidines to the TMS cyanation reaction using aldehydic 
compounds indicates that a C2-symmetrical bicyclic guanidine 15g was found to be the most 
effective catalyst (Scheme 44).37
 
Scheme 44. Enantioselective TMS cyanation reactions of various carbonyl compounds catalyzed by 
bicyclic guanidine 15g. 
 
 
2.7.6 Michael reaction 
Utility of modified guanidines as clean chiral superbase in asymmetric Michael reaction 
under mild reaction conditions was investigated. Reaction of tert-butyl diphenyliminoacetate 
and ethyl acrylate in the presence of 11a or 11d gave high enantioselectivity (97 % ee) (Table 
2).38
X-ray ananlysis and experimental evidence gave the explanation of good enantioselectivity 
in the guanidine-catalyzed Michael reaction: (i) the imino nitrogen atom of guanidine forms 
hydrogen bond to the pro-S hydrogen of the methylene group in the iminoacetate, (ii) alcoholic 
hydrogen of the substituent on the imino nitrogen forms hydrogen bond to the ester carbonyl 
group of the iminoacetated, (iii) the phenyl pendant on the imidazolidine ring forms weak bond 
with one of the diphenyl functions of diphenyliminoacetate through phenyl-phenyl interaction 
(Figure 9). 
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Table 2. Enantioselective conjugate additions of glycinate to various acceptors. 
 
 
Figure 9. Supposed transition state of 11d-catalyzed Michael reaction. 
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Michael reaction of 2-cyclopenten-1-one with dibenzyl malonate in presence of 
monocyclic guanidines 11a was screened.39 With optimization condition, the best result was 
obtained with 43% ee when 11a was used as a catalyst (Scheme 45). 
 
Scheme 45. Guanidine 11a catalyzed Michael reactions between 2-cyclopenten-1-one and dibenzyl 
malonates. 
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The chiral guanidine carrying 2-methylphenyl pendants ent-11d acts as a more effective 
catalyst than 11a with phenyl pendants for the construction of quaternary carbon center in 
chroman ring system by intramolecular Michael-type cyclization (Scheme 46).40
 
Scheme 46. Generation of chromane through guanidine ent-11d catalyzed intramolecular oxa-Michael 
cycization reaction. 
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Chapter 3．Reported Asymmetric Synthesis of 2H-Azirines 
 
2H-Azirine is the smallest unsaturated nitrogen heterocycle, which has been extensively 
explored due to the high ring strain in the wide range of reactions such as cycloaddition, 
ring-opening, thermal rearrangement, and so on. Methods for the synthesis of azirines include: 
a: Neber rearrangement of oxime sulfonates,41 b: Pyrolysis or photolysis of vinyl azides,42 c: 
Elimination reaction of aziridine derivatives,43 d: Ring contraction of isoxazoles,44 e: Ring 
contraction of azete derivatives,45 f: Intermolecular reactions between nitriles and carbenes,46 g: 
Intermolecular reactions between nitrenes and acetylenes,47 and h: Intramolecuar azirination of 
enamine derivatives via nitrenes48 (Figure 10). Among these synthetic methods Neber reaction 
and elimination reaction were applied to the asymmetric version. 
 
Figure 10. General strategies for the construction of 2H-azirine skeleton. 
 
3.1 Asymmetric Neber Reaction. 
The base-induced rearrangement of O-acylated ketoximes to the corresponding α-amino 
ketones is known as the Neber rearrangement. Since its discovery, the rearrangement has 
become an important tool in the synthesis of 2H-azirines.  
 
3.1.1 A chiral auxiliary mediated asymmetric Neber reaction. 
The first example of asymmetric Neber reaction was reported using an O-mesyl 
amidoxime 24 which phenylglycine unit as a chiral auxiliary in which a de of 92% was 
observed (Scheme 47).49 
 
Scheme 47. The first example of synthesis of optically active azirine. 
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 3.1.2 Asymmetric synthesis of 2H-azirine by an alkaloid-mediated Neber 
reaction. 
Various bases were investigated for enatioselective azirine synthesis via Neber reaction 
by Zwanenberg. Treatment of ketoxime tosylates 26 with quinidine leads to 2H-azirine 27 
predominantly to the (R)-enantiomer (up to 82% ee).50 It is suggested that hydrogen bonding 
between the hydroxyl group of base and the substrate is a governing factor in the 
enantiodifferentiation during the abstraction of the methylene protons (Scheme 48) 
 
Scheme 48. Enatioselective 2H-azirine synthesis via Neber reaction. 
 
 
3.1.3 Asymmetric synthesis of 2H-azirine derived from phosphine oxides 
using solid-supported amines. 
Palacios et al. reported the modified enantioselective Neber reaction of tosylketoximes 
phosphonates 28 and 30 to afford 2H-azirinyl phosphonates 29 and 31. When the 
solid-supported amines 32 was applied, low enantioselectivity was observerd (Scheme 49).51
 
Scheme 49. Enantioselective synthesis of 2H-azirinyl phosphonates. 
 
 
3.1.4 Asymmetric synthesis of 2H-azirine by alkaloid-mediated Neber 
reaction. 
The Neber reaction is usually carried out in ethanolic sodium ethoxide and the plausible 
mechanistic pathways have been classified as followed: (Scheme 50) 
(a) Initial removal of α-proton followed by loss of the tosylate moiety produces unsaturated 
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nitrene, which is converted to an azirine (nitrene pathway). 
(b) Displacement at nitrogen and leaving of the tosyloxy function take place in a concerted 
manner after α-proton abstraction (anion pathway). The anti-displacement would be strongly 
favored over the syn-displacement. 
 
 
Scheme 50. Plausible mechanistic pathways of Neber reaction. 
 
According to the proposed mechanism, Maruoka et al. utilized phase transfer conditions 
for Neber rearrangement of ketoxime sulfonate 33, firstly demonstrated the substantial 
involvement of anion pathway in this reaction.52 The stereoselectivity could be rationalized 
based on the conformation of the catalyst-substrate ion pair which would be fixed by the 
possible π-π interaction (Scheme 51). 
 
 
Scheme 51. Phase-transfer catalysis for enantioselective Neber rearrangement. 
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3.2 Elimination of the sulfinyl group in chiral nonracemic 
N-sulfinylaziridines. 
In 1995, Davis and co-workers53 developed a remarkable route to synthesis of 
enantiomerically rich azirines. Treatment of (2S,3S)-(+)-39 with LDA for 20 min and quenched 
with H2O afforded (S)-(+)-2-carbomethoxy-3-phenyl-2H-azirine (39) in 47% yield. When the 
reaction was carried out in the presence of 2 equiv of iodomethane, the yield was improved to 
52%. With this method, attempts to the enantioselective synthesis of the marine cytotoxic 
antibiotic (R)-(-)-dysidazirine was successfully completed by this group (Scheme 52, vide 
infra). 
 
Scheme 52. Synthesis of enantiomerically rich azirines with LDA. 
 
 
3.3 Application to natural 2H-azirine synthesis 
It is known that azirine skeletons appear in natural Azirinomycin (40), an 
azacyclopropene antibiotic, was isolated as the first example of natural product with 2H-azirine 
group from a strain of the soil bacterium Streptomyces aureus in 1971.54 
(-)-(2R)-(E)-Dysidazinrine (41), which exhibiting potent antifungal activity, was isolated from 
the marine sponge Dysidea fragilis in 1987,55 and since then, some bioactive 2H-azirine 
compounds were isolated (Figure 11).56
 
Figure 11. Reprensentative examples of natural products with 2H-azirine. 
 
 
(E)-Dysidazirine, was firstly asymmetrically synthesized in 1995 by Davis and 
co-workers,53 in which the key azirine ring was formed by treating an appropriately substituted 
N-(p-tolylsulfinyl)-2-carbomethoxyaziridine (2R,3R)-(-)-50 with lithium diisopropylamide 
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(LDA), the required aziridine (2R,3R)-(-)-50 was prepared by treatment of sulfinimine (R)-49 
with the lithium enolate of methyl bromoacetate (Scheme 47). Rencently, Molinski et al.47 
reported the total synthesis of 42 and other derivers with a strategy based on asymmetric 
cinchona-alkaloid catalyzed Neber reaction (Scheme 54).50 Asymmetric synthesis of 
2H-azirines still remains a problem for bioactivity natural products synthesis, development of 
new methods and catalysts for asymmetric 2H-azirine synthesis are expected. 
 
 
(R)-(-)-dysidazirine (41)p-Tolyl
S
N
R
O
(R)-(-)-49
R= n-C12H25
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Scheme 53. Synthesis of (R)-(-)-dysidazirine (41) 
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Chapter 4. Trials for Asymmetric Neber Reaction and Related 
Reaction 
 
4.1 Previous works 
In 2000, Ma58 inverstigated asymmetric Neber reaction for the synthesis of 2H-azirine 
catalyzed by chiral guanidines, prepared by Isobe (Table 3). Treatment of ketoxime tosylate 56 
with catalytic amount of TMG in the presence of stoichiometric amount of potassium 
carbonate, gave a 98% yield of product 57 of Neber reaction (entry 1). Then the chiral 
monocyclic guanidine 12b and 58 were studied, however, no enantioselectivity was observed 
(entries 2 and 3). When quinidine was used as a base, 2H-azirine was obtained with modelate 
enantioselectivity, similar to literature50 (entry 4). 
 
Table 3. Chiral guanidine- and quinidine-catalyzed asymmetric synthesis of 2H-azirine by Ma. 
 
 
Asymmetric Neber rearrangement of 56 using chiral guanidines 11a and 11c with 
hydroxy group was also tried, however, desired 2H-azirine 57 was not obtained. Instead, 
α-aminoester 59 was afforded, probably by generation via the ring-opening reaction of 57 with 
methanol, which was added as a co-solvent for azeotropic removal of toluene (Scheme 56). 
 
Scheme 56. Neber reaction catalyzed by chiral guanidines 11a and 11c. 
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4.2 This works 
 
In this thesis, I will not only re-examine the asymmetric Neber reaction, but also approach 
to the related asymmetric synthesis, which could be catalyzed by ChibaG.  
 
4.2.1 Synthesis of (4S,5S)-2-[(1R)-1-Benzyl-2-hydroxyethylimino]- 
1,3-dimethyl-4,5-diphenylimidazolidine (+)-ChibaG (11a).  
 
(+)-ChibaG 11a was prepared according to the reported method as shown in Scheme 60. 
(S,S)-Diamine 67 was reacted with urea at 200 oC to afford the cyclic urea 68 in 78% yield. 
After methylation, imidazolidinone 69 was chlorinated with oxalyl chloride to give the 
corresponding chloroamidinium 70 in high conversion (approximately 70 : 69 = 9 : 1). Then 
the crude 70 was treated with (R)-phenylalaninol (71) in the presence of triethylamine to give 
(+)-ChibaG 11a in 67% yield through 2 steps. 
 
      Scheme 60. Synthesis of (+)-ChibaG 11a from (S,S)-diamine 67. 
 
 
 
4.2.2 Preparation of ketoxime tosylates from β-keto esters. 
A series of acetoacetates was readily converted into the aliphatic ketoxime tosylates in a 
simple two-step procedure in fair yields (Table 4). Ethyl acetoacetate 72a reacted with 
hydroxylamine hydrochloride in the presence of sodium hydroxide (NaOH) to give a ketoxime 
73a, which was immediately tosylated to afford oxime tosylate 74a as a mixture of E/Z isomers 
(major : minor = 65 : 35) (entry 1). Similar treatment of benzyl acetoacetate (72b) with NaOH 
gave only a lower yield of ketoxime tosylate 74b (entry 2). Replacement of base to NaHCO3 
improved the yield of 74b up to 64% (entry 3). Under the same conditions, oxime tosylate 74c 
was obtained from tert-butyl acetoacetate (72c) in 92% yield (entry 4). 
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Table 4. Preparation of ketoxime tosylates 74. 
 
 
Attempt to prepare aromatic ketoxime tosylate 77 from ethyl benzoylacetate (75) was 
examined. Trials using different bases, such as NaOH, NaHCO3 or pyridine were unsuccessful. 
It is known that the oxime 76 is readily cyclize to the corresponding isoxazolone, probably 
because of the preferential syn-hydroxyimino group (Scheme 61). 
 
Scheme 61. Trials for preparation of ketoxime tosylate 77. 
 
 
4.2.3 Preliminary examination of Neber reaction with TMG or Et3N 
On oxime tosylates prepared, synthesis of 2H-azirines was performed with TMG or Et3N 
(Table 5). Reaction of ketoxime tosylate 74a with 0.1 Meq of TMG led to the formation of 
2H-azirine 78a in 45% yield after bulb-to-bulb distillation (entry 1). When Et3N was used as a 
base, no promotion was observed (entry 2). Treatment of tert-butyl ketoxime tosylate 74c in 
the presence of TMG affords 78c in 79% yield (entry 3). When benzyl ketoxime tosylate 74b 
was used as a substrate, product 78b was not formed (entry 4).  
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Table 5. Synthesis of 2H-azirine with TMG or Et3N. 
 
 
4.2.4 Trials for asymmetric Neber reaction 
 Since oxime tosylate 74c gave the good yield of 2H-azirine 78c, chiral bases were applied 
to this reaction (Table 6). However only a low stereoselectivity (5～6% ee) was observed with 
(+)-ChibaG 11a (entries 1, 2) even smooth reaction. Improved chemical yield and 
enantioselectivity were observed when quinidine was subjected to the reaction (entry 3).50
 
Table 6. Trials for asymmetric Neber reaction 
 
 
As discussed in Chapter 1, ChibaG 11a was an efficient catalyst in Michael reaction. The 
low enantioselectivity in this reaction possibly come from small or no π-π interaction between 
oxime tosylate 74c and ChibaG. Thus, aromatic substituted oxime would be more potential in 
this reaction. 
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4.2.5 Trials for the synthesis of 2H-azirine from ethyl 
1,2-benzisoxazol-3-ylacetate 
Since attempt of synthesis of phenyl oxime tosylate 77 from ethyl benzoylacetate 75 was 
failed, as mentioned aboved, benzisoxazole 81 was candidated as an alternative substrate in 
chiral guanidine-catalyzed Neber reaction. 1,2-Benzisoxazole 81 was prepared from 
4-hydroxycoumarin 79 via Posner reaction, followed by esterification according to the 
literature (Scheme 62).59
 
Scheme 62. Preparation of benzisoxazole 81 from 4-hydroxycoumarin 79. 
 
 
Firstly, TMG-catalyzed azirination reaction of 81 was examined at room temperature, but 
no change was found even after four days. The low reactivity would be due to the stronger N-O 
bond of benzisoxazole than that of oxime tosylate (entry 1 in Table 7). A series of Lewis acid 
was reported to cleave the isoxazole N-O bond giving β-hydroxy ketones or β-aminoesters.60 
Thus, reactions in the presence of several Lewis acid TMSCl, BF3·OEt2, ZnI2 or FeCl2·4H2O 
were examined (entry 2-6). However, no reaction was detected, except in the case of TMSI, 
which gave deesterification product 80 (entry 3). These observations indicate that the N-O 
bond in 81 could not be cleaved with Lewis acid and TMG. Therefore, trials to prepare 
aromatic substituent were given up. 
 
  Table 7. Trials for synthesis of 2H-azirine from ethyl 1,2-benzisoxazol-3-ylacetate (81) 
TMG (0.2 Meq.)
Lewis acid (2.0 Meq.)
CH2Cl2, rt
resultentry
2 NRTMSCl
time (d)
2
82
Lewis acid
O
N
CO2Et OH
CO2Et
N
3 80: 66%TMSI 2
4 NRBF3.OEt2 1
5 NRZnI2 1
6 NRFeCl2.4H2O 1
81
1 NR4
 
 
On the other hand, alkylation of benzoisoxazole 81 was also examined (Table 8). The use 
of TMG as a base afford an alkylated products 82 in a low yield (entry 1) or no reaction was 
occurred (entry 2), NaH was effective for the reaction to give a product in moderate yields 
(entries 3,4).  
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Table 8. Methylation and benzylation of benzisoxazole 81. 
 
 
 
 
4.2.6 Trials for Intermolecular Electrophilic Amination of β-carbonyl esters 
with Oxime 
Next, intermolecular electrophilic amination of β-carbonyl esters with oxime tosylates 
was designed. Benzophenone oxime tosylate 89 with trifluoromethyl substituent at p-position 
was chosen as a substrate. Synthesis of a precursor, benzhydrol 86 was at first attempted via 
Grignard reaction of aldehyde 85 and Grignard reagent 84a, but desired alcohol 86 afforded 
only in 11% yield, so, we changed into the methods using nBuLi as a stronger base to result in 
a 78% yield of alcohol 86 (Scheme 63). A desired oxime tosylate 89 was obtained via 
oxidation followed by oxime formation and tosylation. (Scheme 64) 
 
Scheme 63. Synthesis of alcohol 86 using Grignard reagent or nBuLi. 
 
 
Scheme 64.Synthesis of oxime tosylate 89 from 86. 
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Next, intermolecular electrophilic amination of β-carbonyl esters 90 and 92 with 89 were 
examined at room temperature using TMG or NaH as a base. However, no reactions were 
observed in these reactions (Scheme 65). 
 
Scheme 65. Intermolecular electrophilic amination of β-carbonyl esters 90 and 92 with 89. 
 
 
As an alternative substrate, an oxime triflate 96, with better leaving group than 89 was 
designed. Reaction of benzophone 94 and hydroxylamine gave oxime 95, but some efforts for 
triflation were failed, instead only a complex mixture was obtained (Scheme 66). 
 
Scheme 66. Preparation of oxime 96. 
 
 
Then aliphatic oxime tosylate 99 derived from acetone 97 was prepared by conventional 
method in 78% yield via oxime 98. Intermolecular electrophilic amination was examined using 
β-carbonyl ester 90, but, to our disappointment, no reaction was detected (Scheme 67). 
 
Scheme 67. Trial for intermolecular electrophilic amination of β-carbonyl esters 90 with 99. 
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4.2.7 Trials for TMG-catalyzed Michael reaction of ketoxime ester 
  Since β-keto oxime ester could form the corresponding enolates under basic condition, we 
applied a TMG-catalyzed Michael reaction. To examine this approach, O-methyl oxime 101 
was prepared in a common way to the oxime derivative (Scheme 68). 
 
Scheme 68.Preparation of O-methyl oxime 101. 
 
Firstly, air-oxidation of O-methyl oxime 101 was examined in the presence of TMG as a 
base catalyst. However, the trial was proved unsuccessful in different solvents such as CH2Cl2, 
DMF, and THF, no reaction was detected (Scheme 69). 
 
Scheme 69. Oxygenation O-methyl oxime 101. 
 
On the other hand, as expected, treatment of O-methyl oxime 101 with methyl vinyl 
ketone in the presence of TMG for 7 days gave the corresponding Michael adduct 103 in 57% 
yield (Table 9, entry 1). The same reaction with shorter period (2 days) gave similar result 
(entry 2). We next checked the reactivity of this reaction in different solvents, and 60% yield of 
the product was obtained under no solvent condition (entry 5). 
 
Table 9. Michael addition reaction of O-methyl oxime 101 with methyl vinyl ketone. 
 
 
Next, attempt to increase the reactivity of TMG-catalyzed Michael reaction of ketoxime 
ester was examined. It’s expected that change of the oxime substitutent on 101 to electron 
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withdraw group such as 2,4-dinitrophenyl group would increase the reactivity. An O-aromatic 
oxime 104 was proposed as shown in Scheme 70. Reaction of N-hydroxyphthalimide 105 with 
dinitrochlorobenzene 106 afforded 107 in 85% yield, trials of deprotection of 107 with 
hydrazine hydrate and ammonia were unsuccessful. A complex mixture was generated in each 
case (Scheme 71). 
 
Scheme 70. Synthetic trials toward O-aromatic oxime 104. 
 
 
 
To test the reactivity of ketoxime tosylate 74c, alkylation of 74c was examined with 
benzyl bromide, however, this reaction gave only Neber product 78c (Scheme 71). 
 
Scheme 71. Trials for benzylation of ketoxime tosylate 74c. 
 
 
 
4.2.8 Conclusion. 
1. Chiral guanidine-catalyzed asymmetric Neber reactions were investigated, and only a low 
steroselectivity was observed when ChibaG 11a was used as a catalyst.  
2. Trials for intermolecular electrophilic amination of β-carbonyl esters using various 
ketoxime tosylates in the presence of TMG were unsuccessful. No reaction was observed. 
3. On the trials for TMG-catalyzed Michael reaction of O-methyl oxime esters and methyl 
vinyl was given the corresponding Michael adducts.  
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Chapter 5．Studies on Guanidine-Catalyzed Asymmetric Micheal 
Reactions 
 
Nicotine (110) and nornicotine (111) are typical alkaloid components of tobacco, which 
play important roles as chemical mediators in nervous system.61 The first synthesis of 110 was 
given by Pictet in 1904, 62 after when many of the chemists have devoted to construct the 
2-arylpyrrolidine ring system with intense interest63 because of the widespread occurrence of 
the structurally related 5-arylprolines in nature.64 The synthetic strategy for 2-arylpyrrolidine 
ring system is roughly classified into 4 categories (Scheme 71): pyrrolidine ring construction 
by either (i) 1-functionalized 4-amino-1-arylbutanes (method I)65 or (ii) 4-functionalized 
1-amino-1-arylbutanes (method II),66 and introduction of aryl unit to pyrrolidine ring by either 
(iii) direct insertion (method III)67 or (iv) modification of proline derivatives (method IV).68 
The first asymmetric synthesis of nicotine skeleton was achieved in the synthesis of 
nornicotine (2) from proline by application of method IV in 1982.68 Diastereoselective 
alkylation of ketimine template derived from (3-pyridinyl)methylamine,66g cyclization of 
4-azido-4-(3-pyridinyl)-1-butene derived from the corresponding homoallyl alcohol obtained 
by asymmetric allylation of pyridine-3-carbaldehyde,66h and ring closure metathesis of 
3-allylamino-(3-pyridinyl)-1-propene obtained by asymmetric amination of 3-(3-pyridinyl)allyl 
alcohol66i were reported as asymmetric synthesis of nicotine systems belong to method II. Loh 
et al65d the diastereoselective synthesis of nornicotine (111) from 
1-(3-pyridinyl)butan-1,4-dione by method I, in which an aminosugar was used as a chiral 
source. The uses of glutamates and pyroglutamates as chiral sources were common approaches 
to diastereoselective constructions of chiral 5-arylprolinates belong to method I.65e-g, i-j As other 
chiral sources in the preparation of 5-arylprolinates by method I, an allylamine prepared by 
diastereoselective Overman rearrangemen65c and a propargyl amino acid65h were used. 
Although asymmetric phenylation of pyrrole67b and Heck phenylation of a chiral 
dihydropyrrole67a belong to method III were also applied to the construction of 
5-phenylprolinates, there have been no reports of asymmetric synthesis catalyzed with 
organocatalysis. 
 
Scheme 71. Classification of Construction Methods for Nicotine and 5-Arylprolinate System 
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Guanidine is a strong organobase and, thus, play an important role as a base catalyst in 
organic synthesis.2 As a part of our ongoing study of guanidine-catalyzed asymmetric synthesis 
ChibaG was applied to the Michael reaction of diphenyliminoacetate and 2-pyridyl vinyl 
ketone for construction of 5-pyridylproline system. We herein report the first example of 
organobase-catalyzed synthesis of 5-arylproline derivative. 
 
Results and Discussion 
Our retrosynthetic analysis for the construction of nicotine system is outlined in Scheme 72, 
in which (S)-5-t-butoxycarbonyl-2-pyridyl-1,2-dehydropyrrolidine (112), leadable to nicotine 
(110) and nornicotine (111), would be afforded by the cyclization of a Michael adduct 113 from 
3-pyridyl vinyl ketone (114) and t-butyl diphenyliminoacetate (115).  
 
Scheme 72. Retrosynthesis of (S)-nicotine (110) and (S)-nornicotine (111) via ChibaG (11a)-catalyzed 
enantioselective Michael reaction of pyridyl vinyl ketone 114 and iminoacetate 115. 
 
 
In the preparation of pyridyl vinyl ketone 114, although Grignard reaction of Weinreb 
amide 116, derived from nicotinoyl chloride and N,O-dimethylhydroxylamine hydrochloride in 
87% yield, with vinylmagnesium bromide failed, oxidation of allyl alcohol 117, obtained by 
Grignard reaction of pyridinecarbaldehyde with vinylmagnesium bromide in 98% yield, either 
manganese oxide (MnO2) or 2-iodoxybenzoic acid (IBX) successfully gave a desired vinyl 
ketone 114 (Scheme 73), which was found to not only be sensible to air but also easily 
polymerize during purification by chromatography. Thus, pyridyl vinyl ketone 114 was used as 
a Michael acceptor in the reaction with iminoacetate 115 without further purification.   
*Production of only complex mixture was observed under the conditions of Swern and 
Dess-Martin oxidation in addition to other oxidation using PCC and TPAP.  
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Scheme 73. Synthesis of pyridyl vinyl ketone 114. 
 
 
Preliminary examination of (+)-ChibaG (11a)-catalyzed Michael reaction of iminoacetate 
115 using a crude pyridyl vinyl ketone 114 showed that a Michael adduct 113 was partially 
hydrolyze to give a dehydropyrrolidine derivative 112 during purification under 
chromatographic conditions. Estimation of enantioselectivity in a crude adduct 113 using chiral 
HPLC [column:CHIRALPAK AD-H, eluent: n-hexane: 2-propanol = 9:1, flow rate: 1.0 ml/min, 
detection: 254 nm, retention time: 7.3 min (S) and 7.8 min (R)], as expected, allowed us to 
deduce high asymmetric induction (ca 93-98% ee) in the (+)-ChibaG (11a)-catalyzed Michael 
reaction. Therefore, we decided to directly prepare a dehydropyrrolidine derivative 112 from 
ally alcohol 117 in overall three steps (Table 10).   
The crude 114, obtained by refluxing in dichloromethane with MnO2 for 24 h (step 1), 
was treated with an equimolar amount of iminoacetate 115 in tetrahydrofuran (THF) at – 15 °C 
for 3 days in the presence of 20 mol% of (+)-ChibaG (11a) to give a Michael adduct (step 2) 
and successive acid hydrolysis with aqueous acetic acid and THF (step 3) afforded 
dehydropyrrolidine 112 in 33% overall yield and with 81% ee (entry 1), suggesting that partial 
epimerization is occurred during the acid hydrolysis in step 3. The use of 15% citric acid in 
THF in step 3 slightly improved the product formation (43%) and enantioselectivity (89% ee) 
(entry 3). Oxidation of 117 with MnO2 in place of IBX in step 1 afforded a better result (entry 
3).  Fine tunings for moler ratios of the catalyst and/or a Michael donor 115 resulted in the 
uses of 10 mol% of 11a and 200 mol% of iminoacetate 115 as the optimum condition, in which 
dehydropyrrolidine 112 was given in 73% and 94% ee (entry 8). It is known that the 
stereogenic center of an adduct obtained in intermolecular Michael reaction using iminoacetate 
115 is controlled by the chiral center of the 2-imino substituent, but not those of  
imidazolidine ring, in (+)-ChibaG (11a)-type catalyst. Thus, in this case 
(S)-1,5-dehydroprolinate 112 could be produced. In addition, dextrorotaory in the optical 
rotation of 112 ([α]D -90.0 (c 0.5, CH2Cl2)) strongly supported R configuration of the newly 
born stereogenic center by comparision of that of a related methyl 
(S)-5-(3-pyridinyl)-3,4-dihydro-2H-pyrrolecarboxylate ([α]D -82.7 (c 0.5, CH2Cl2)).65h  
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Table 10. Prepration of dehydropyrrolidine 4 from allylalcohol 9 through ChibaG (3)-catalyzed Michael 
reaction 
   
 
Catalytic hydrogenation of 1,5-dehydroprolinate 112 smoothly afforded reduction 
product 118 as a sole product, the cis-configuration of which was assigned by 1H NMR 
spectrum compared to literature data,65f in which similar chemical shifts and coupling 
constants were observed between cis isomer (120a) and 118 (Table 11). Deprotection of t-butyl 
ester function of 118 with trifluoroacetic acid afforded 5-(3-Pyridyl)proline 119 ([α]D -34.4 (c 
0.5, H2O)) as a trifluoroacetic acid salt (Scheme 74). Thus, the formal asymmetric synthesis of 
nicotine system was achieved becaused 119 had been converted to nicotine (110).  
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Scheme 74. Conversion of (S)-dehydroprolinate 112 to (2S,5S)-5-(3-pyridyl)proline 119. 
 
 
Table 11. Comparision of part of 1H NMR data for 120a, 120b and 118. 
 
 
In summary, we succeeded in simple preparation of 5-arylproline derivative using 
guanidine-catalyzed Michael reaction of iminoacetate and 3-pyridyl vinyl ketone as a key 
reaction. This is the first application of organocatalysis to the construction of nicotine system. 
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Chapter 6: Experimental Section  
 
 
 
General.  
All reactions were carried out under an atmosphere of dry argon, unless stated otherwise. 
Analytical thin layer chromatography (TLC) was performed on Merck silica gel 60 F254 
and Fuji silysia NH-silica gel 60 F254 glass plates precoated with a fluorescent indicator. 
Column chromatography was performed using silica gel 60 (63-210 μm) from Kanto-Cica or 
NH-silica gel (100-200 mesh) from Fujji silysia. Melting points were measured on a Yanaco 
micro melting point apparatus and were uncorrected. HPLC was performed on a Jasco 
Gulliver-series instrument equipped with a variable wavelength detector and Daicel Chiracel 
AD-H column. Optical rotations were measured on a Jasco P-1020 polarimeter with a sodium 
lamp, and were reported as follows: [α]DT (c g/ 100 ml, solvent). IR spectra were recorded as a 
thin film between NaCl plates, KBr plates or ATR method on a Jasco FTIR 300E 
spectrophotometer. 1H NMR spectra and 13C NMR spectra were recorded on a JOEL 
JNM-ECP400, JNM-A400SW, or JNM-GSX500A spectrometer. Chemical shifts for protons 
and carbons were reported in part per million (ppm) downfield from tetramethylsilane and 
were calibrated at δ 0.00 and 77.00 ppm). Data were presented as follows: chemical shift, 
multiplicity (br= broad, s= singlet, d= doublet, t= triplet, m= multiplet), coupling constants in 
Hertz (Hz) and integration. Low resolution mass spectra were obtained on a JOEL JMS-AX 
500-505 and high resolution mass spectra were obtained on a JOEL JMS-HX110A. 
 
 
(4S,5S)-4,5-Diphenylimidazolidin-2-one (68) 
A mixture of diamine 67 (1.01g, 4.76 mmol, 1.0 Meq.) and urea (318.1 mg, 5.30 mmol, 1.1 
Meq.) was stirred at 200oC under argon atmosphere for 4 h. The reaction mixture was cold to 
room temperature, after the reaction mixture was diluted with CH2Cl2 (20 ml), the whole was 
washed with water (20 ml) and extracted with CH2Cl2 (20 ml×3). The combined extracts were 
washed with brine (20 ml), dried over MgSO4, then dichloromethane was removed in vacuo, 
and recrystallization of the residual solid from AcOEt gave colorless needles 68 (0.88 g, 
77.6%). 
Mp 201-203 oC; Rf = 0.43 (SiO2, AcOEt ); IR υmax cm-1: 1700(C=O);  
1H-NMR (400 MHz, CDCl3): δ  (ppm) 4.61 (2H, s, CH×2), 5.01 (2H, brs, NH×2), 7.26-7.29 
(4H, m, ArH), 7.34-7.40 (6H, m, ArH). 
 
 
(4S,5S)-1,3-Dimethyl-4,5-diphenyl-2-imidazolidinone (69) 
To a suspension of NaH (304.9 mg, 7.62 mmol, 2.2 Meq.) in DMF (10 ml) under argon 
atmosphere, was added portionwise (4S,5S)-diphenylimidazolidine-2-one 68 (800 mg, 3.36 
mmol, 1.0 Meq.) and the mixture was stirred at room temperature for 40 min. After addition of 
iodomethane (0.5 ml, 7.62 mmol, 2.2 Meq.), the mixture was stirred 18 h at room temperature. 
After the reaction was poured into 5% HCl, and extracted with CH2Cl2 (10 ml×3). The 
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combined extracts were washed with brine (10 ml), dried over MgSO4 and CH2Cl2 was 
removed in vacuo, the resulting residue was purified by column chromatography (n-Hexane: 
AcOEt= 2:1) to obtain a color prisms 69 (788.3 mg, 88.2%).  
Mp 150-153 oC; Rf= 0.61(SiO2, n-Hexane:AcOEt = 2:1); IR υmax cm-1: 1706 (C=O) 
1H NMR (400 MHz, CDCl3): δ (ppm) 2.67 (6H, s, N-CH3×2), 4.05 (2H, s, CH×2), 7.10-7.12 
(4H, m, ArH), 7.30-7.34 (6H, m, ArH). 
 
 
(4S,5S)-2-Chloro-1,3-Dimethyl-4,5-diphenylimidazolidinium chloride (70) 
To a suspension of 69 (600 mg, 2.25 mmol, 1.0 Meq.) in anhydrous benzene (6 ml) under 
argon atmosphere, oxalyl chloride (0.96 ml, 11.26 mmol, 5.0 Meq.) was added dropwise. The 
resulting pale yellow solution was heated at 80oC for 14h. The reaction mixture was 
concentrated to dryness and the resulting white solids (741.6 mg) was used in the next step 
without purification (the percentage of conversion was estimated by 1H-NMR analysis to 
indicate the ratio of 2:1 = 88.9: 11.1). 
1H NMR (400 MHz, CDCl3): δ (ppm) 3.21 (6H, s, N-CH3×2), 5.29 (2H, s, CH×2), 7.36-7.56 
(10H, m, ArH). 
 
 
(4S,5S)-2-[(1R)-1-Benzyl-2-hydroxyethylimino]-1,3-Dimethyl-4,5-diphenylimidazolidin
e (11a) 
To a solution of (R)-phenylalaninol (347.3 mg, 2.31 mmol, 1.0 Meq.) and triethylamine 
(0.64 ml, 4.62 mmol, 2.0 Meq.) in CH2Cl2 (4 ml) was added dropwise a solution of 70 (741.6 
mg) in CH2Cl2 (3 ml) at 0oC. The mixture was stirred at rt for 6 h, then ice cold to 0oC, 
acidified with 10% HCl up to pH<3, and extracted with CH2Cl2 (10 ml×3) three times. The 
orgnic layer was evaporated to dryness. The residue was dissolved in water (10 ml) and washed 
with toluene (10 ml×2).  
The combined toluene extracts was washed with H2O (10 ml), brine (10 ml), dried over 
MgSO4 and concentrated to afford pale yellow solids of 
(4S,5S)-1,3-Dimethyl-4,5-diphenyl-2-imidazolidinone.  
The aqueous solution was basified (pH>11) by 20% NaOH and extracted with toluene (10 
ml×3). The toluene solution was washed with H2O (10 ml), dried over MgSO4 and 
concentrated to afford 11a as a colorless prism (598.7 mg, 66.6%). 
Mp 111-114 oC; IR υmax cm-1:1641 (C=N); 
1H NMR (400 MHz, CDCl3): δ (ppm) 2.60 (3H, s, N-CH3), 2.77 (3H, s, N-CH3), 2.82 (2H, d, J 
= 6.8 Hz, CH2Ph), 3.59-3.63 (2H, dd, J = 10.1, 6.0 Hz), 3.69-3.73 (1H, J = 10.1, 4.2 Hz), 3.83 
(1H, s), 4.27 (1H, m, NCH), 7.08-7.7.36 (15H, m, ArH);  
13C NMR (100 MHz, CDCl3): δ (ppm) 40.2, 57.3, 66.1, 125.9, 127.4, 128.1, 128.5, 129.7, 
138.3, 140.0, 157.9. 
 
 
Ethyl 3-(4-tolylsulfonyloximino)butanoate (74a) 
Keto ester 72a (3.0 ml, 23.05 mmol) was gradually added to a solution of 
hydroxylamine.HCl (1.77 g, 25.5 mmol, 1.1 Meq.) and NaOH (1.02 g, 25.6 mmol, 1.1Meq.) in 
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60% aqueous MeOH (30ml). After 30 min the solvent was removed under reduce pressue and 
the residue was extracted 3 times with AcOEt (40ml). The combined organic layers were dried 
over MgSO4 and concentrated in vacuo. The crude ketoxime was dissolved immediately in dry 
dichloromethane (30 ml), p-TsCl (4.42 g, 23.18 mmol, 1.0 Meq.) and pyridine (1.87 ml, 23.18 
mmol, 1.0Meq.) were added at room temperature under argon atmosphere. After stirring for 3h, 
sat. NH4Cl (30ml) was added and the mixture was extracted three times with dichloromethane 
(30ml×3). The combined organic layers were washed with brine and dried over MgSO4. 
Concentration in vacuo yielded crude 74a, which were purified by flash chromatography 
(n-Hexane: AcOEt= 2:1) gave ketoxime tosylate 74a (5.83 g, 84.3%) (a mixture of major: 
minor= 65:35). 
Rf = 0.45 (SiO2, n-Hexane:AcOEt=2:1 ); IR υmax cm-1 :1735(C=O); 
1H NMR (400 MHz, CDCl3): δ (ppm) 
major: 1.23 (3H, t, J = 7.1 Hz, CH2CH3), 2.06 (3H, s, CH3), 2.45 (3H, s, Ar-CH3), 3.25 (2H, 
s, CH2), 4.14 (2H, q, J = 7.1 Hz, CH2CH3), 7.33 (2H, d, J = 8.2 Hz, Ar-H), 7.85 (2H, d, J = 8.2 
Hz, Ar-H). 
minor: 1.25 (3H, t, J = 7.1 Hz, CH2CH3), 2.02 (3H, s, CH3), 2.45 (3H, s, Ar-CH3), 3.43 (2H, 
s, CH2), 4.15 (2H, q, J = 7.1 Hz, CH2CH3), 7.33 (2H, d, J = 8.2 Hz, Ar-H), 7.85 (2H, d, J = 8.2 
Hz, Ar-H). 
  
 
Benzyl 3-(4-tolylsulfonyloximino)butanoate (74b) 
Keto ester 72b (3g, 15.61 mmol) was gradually added to a solution of hydroxylamine.HCl 
(1.20g, 17.25 mmol, 1.1Meq.) and NaHCO3 (1.46 g, 17.36 mmol, 1.1Meq.) in 60% aqueous 
MeOH (30ml). After 30 min the solvent was removed under reduce pressue and the residue 
was extracted 3 times with AcOEt (40ml). The combined organic layers were dried over 
MgSO4 and concentrated in vacuo. The crude ketoxime was dissolved immediately in dry 
dichloromethane (30ml), p-TsCl (2.98 g, 15.61 mmol, 1.0 Meq.) and pyridine (1.26 ml, 15.61 
mmol, 1.0Meq.) were added at room temperature under Ar. After stirring for 3h, sat. NH4Cl 
(30ml) was added and the mixture was extracted three times with dichloromethane (30 ml). 
The combined organic layers were washed with brine and dried over MgSO4. Concentration in 
vacuo yielded crude 74b, which were purified by flash chromatography (n-Hexane: AcOEt= 
4:1) gave ketoxime tosylate 74b (3.45 g, 61.2%). (a mixture of major: minor= 88:12) 
Rf = 0.28 (SiO2, n-Hexane:AcOEt=4:1 ) ; IR υmax cm-1 :1737(C=O);  
1H NMR (400 MHz, CDCl3): δ (ppm)  
major: 2.04 (3H, s, CH3), 2.43 (3H, s, Ar-CH3), 3.30 (2H, s, CH2CO2Bn), 5.11 (2H, s, 
OCH2Ph), 7.28-7.36 (7H, m, Ar-H), 7.83 (2H, d, J = 8.2 Hz, Ar-H). 
minor: 2.00 (3H, s, CH3), 2.43 (3H, s, Ar-CH3), 3.49 (2H, s, CH2), 5.11 (2H, s, OCH2Ph), 
7.28-7.36 (7H, m, Ar-H), 7.83 (2H, d, J = 8.2 Hz, Ar-H). 
13C NMR (100 MHz, CDCl3):16.0 (CH3), 21.7 (CH3), 40.7, 67.2, 128.3, 128.5, 128.6, 128.8, 
129.6, 132.5, 135.0, 145.0, 161.5, 167.7. 
HRFABMS: 362.1059 [M+H]+ (Caled for C18H20NO5S : 362.1062) 
 
 
t-Butyl 3-(4-tolylsulfonyloximino)butanoate (74c) 
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Keto ester 72b (3.14ml, 18.9mmol) was gradually added to a solution of 
hydroxylamine.HCl (1.46g, 20.9mmol, 1.1Meq.) and NaHCO3 (1.77g, 21.0mmol, 1.1Meq.) in 
60% aqueous MeOH (30ml). After 30 min the solvent was removed under reduce pressue and 
the residue was extracted 3 times with AcOEt (40ml). The combined organic layers were dried 
over MgSO4 and concentrated in vacuo. The crude ketoxime was dissolved immediately in dry 
dichloromethane (30ml), p-TsCl (3.62g, 19.0mmol, 1.0Meq.) and pyridine (1.55ml, 18.9mmol, 
1.0Meq.) were added at room temperature under Ar. After stirring for 3h, sat. NH4Cl (30ml) 
was added and the mixture was extracted three times with dichloromethane (30ml×3). The 
combined organic layers were washed with brine and dried over MgSO4. Concentration in 
vacuo yielded crude 74c, which were purified by flash chromatography (n-Hexane: AcOEt= 
4:1) gave ketoxime tosylate 74c (5.70g, 17.4mmol, 92.1%) (a mixture of major: minor= 
75:25). 
Mp 89-91 oC; Rf = 0.66 (SiO2, n-Hexane:AcOEt=2:1 ); IR υmax cm-1: 1720(C=O) 
1H NMR (400 MHz, CDCl3): δ (ppm) 
major: 1.40 (9H, s, CH3×3), 2.04 (3H, s, CH3), 2.44 (3H, s, Ar-CH3), 3.17 (2H, s, CH2), 
7.33 (2H, d, J = 8.2 Hz, Ar-H), 7.85 (2H, d, J = 8.2 Hz, Ar-H). 
minor: 1.43 (9H, s, CH3×3), 2.01 (3H, s, CH3), 2.44 (3H, s, Ar-CH3), 3.35 (2H, s, CH2), 
7.33 (2H, d, J = 8.2 Hz, Ar-H), 7.85 (2H, d, J = 8.2 Hz, Ar-H). 
 
 
Ethyl 3-methyl-2H-azirine-2-carboxylate (78a) 
To a stirred solution of ketoxime tosylate 74a (1.03 g, 3.45 mmol, 1.0 Meq.) and K2CO3 
(556.2mg, 4.02 mmol, 1.2 Meq.) in dry CH2Cl2 (8 ml) at -15oC under Ar, was added TMG 
(0.042 ml, 0.334 mmol, 0.1 Meq. ) in CH2Cl2 (2 ml). After stirred 30 min, the reaction solution 
was allowed up to room temperature for 8 h. The mixtrue was diluted with sat. NH4Cl (10 ml), 
then extracted three times with CH2Cl2 (10 ml), the combined organic layers were washed with 
brine (10 ml), dried over MgSO4 and concentrated in vacuo to give a residue oil. The crude 
product was purified by bulb to bulb distillation (70oC/10 mmHg), obtain a colorless oil 78a 
(199.1 mg, 45.4%)  
Rf = 0.69 (SiO2, n-Hexane:AcOEt=2:1 ); IR υmax cm-1: 1797 (C=N), 1724 (C=O), 1189 
(C-O); 1H NMR (400 MHz, CDCl3): δ (ppm) 1.28 (3H, t, J = 7.2 Hz, CH2CH3), 2.44 (1H, s, 
CH), 2.53 (3H, brs, CH3), 4.17, 4.21 (each 1H, dq, J = 10.8, 7.2 Hz, CH2CH3) 
 
 
t-Butyl 3-methyl-2H-azirine-2-carboxylate (78c) 
To a stirred solution of ketoxime tosylate 74c (99.0 mg, 0.302 mmol, 1.0 Meq.) and K2CO3 
(62.1 mg, 0.449 mmol, 1.5 Meq.) in dry toluene (0.5 ml) at -15oC under Ar, was added 
guanidine 2 (25.9 mg, 0.065 mmol, 0.2 Meq.) in toluene (0.5 ml). After stirred 30 min, the 
reaction solution was allowed up to room temperature for 8 h. the mixtrue was diluted with sat. 
NH4Cl (5 ml), then extracted three times with AcOEt (5 ml), the combined organic layers were 
washed with brine (10 ml), dried over MgSO4 and concentrated in vacuo to give a residue oil. 
The crude product was purified by bulb to bulb distillation (100-110oC/3-4 mmHg), obtain a 
colorless oil 78c (31.2 mg, 67.0%, 6.0% ee).  
ee value was determined by GLC analysis using a chiral column (GC capiliary column 
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CP-cyclodextrin-B, retention time: 11.0min, 11.7min, oven: 100oC, inject: 200oC, detect: 
200oC) 
Rf = 0.47 (SiO2, n-Hexane:AcOEt=4:1 ); IR υmax cm-1 :1797(C=N), 1722(C=O), 1157(C-O); 
1H NMR (400 MHz, CDCl3): δ (ppm) 1.48 (9H, s, CH3x3), 2.35 (1H, s, CH), 2.52 (3H, s, 
CH3). 
 
 
1,2-Benzisoxazole-3-acetic acid (80) 
4-hydroxycoumarin (101.4 mg, 0.625 mmol) was dissolved in a solution of free 
hydroxylamine obtained from EtOH/EtONa (1 ml) and NH2OH.HCl (128.7 mg, 1.85 mmol, 
3.0 Meq.) under Ar. The solution was refluxed 7 h, then evaporated, the residue added with an 
aqueous solution of NaHCO3 (10 ml) and washed with AcOEt (10 ml) for 3 times. The alkaline 
solution was acidified with 2N HCl up to pH<3, then extracted with AcOEt (10 ml) for 3 times. 
The combined extracts were washed with brine (5 ml), dried with MgSO4, evaporated in vacuo. 
The residual crude was recrystallized from AcOEt, 80 was obtained as a pale yellow solide 
(97.3 mg, 0.549 mmol, 87.9%). 
Mp 129-131 oC; Rf = 0.75 (SiO2, n-Hexane:AcOEt =2:1); IR υmax cm-1:1729 (C=O) 
1H NMR (400 MHz, CDCl3): δ (ppm) 4.10 (2H, s, CH2), 7.32-7.36 (1H, m, Ar-H), 7.55-7.58 
(2H, m, Ar-H), 7.70 (1H, d, J = 7.9 Hz, Ar-H); EIMS m/z: 177 [M+, (89.2%)], 133 (100.0%), 
120 (33.2%), 104 (44.6%) 
 
 
Ethyl 1,2-benzisoxazol-3-ylacetate (81) 
To a solution of 1,2-benzisoxazole-3-acetic acid 80 (4.03 g, 22.74 mmol, 1.0 Meq.) in EtOH 
(30 ml), con. H2SO4 (0.4 ml, 7.5 mmol, 0.34 Meq.) in EtOH (10 ml) was added dropwise at 
0oC. The solution was refluxed 2 days, then evaporated the EtOH, after the residue was diluted 
with CH2Cl2 (20 ml), the solution was basified with sat. NaHCO3 up to pH>8, after seperation, 
the orgnic layer was extracted with CH2Cl2 (20 ml) for 3 times. The combined extracts were 
washed with brine (20 ml), dried with MgSO4, evaporated in vacuo. The residual crude was 
purified by column chromatography obtain a brown oil 81 (4.02 g, 19.6 mmol, 86.0%). 
Rf = 0.48 [SiO2, n-Hexane:AcOEt =4:1]; IR υmax cm-1: 1735 (C=O) 
1H NMR (400 MHz, CDCl3): δ (ppm) 1.26 (3H, t, J = 7.1 Hz, CH2CH3), 4.04 (2H, brs, CH2), 
4.22 (2H, q, J = 7.1 Hz, CH2CH3), 7.33 (1H, ddd, J = 8.1, 6.2, 1.8 Hz, H-5), 7.55-7.60 (2H, m, 
Ar-H), 7.72 (1H, d, J = 7.1 Hz, Ar-H) 
13C NMR (100 MHz, CDCl3): δ (ppm) 13.4, 31.0, 61.0, 109.2, 120.8, 121.3, 123.0, 129.4, 
152.1, 162.6, 167.7 
 
 
Ethyl (1,2-benzisoxazol-3-yl)methylacetate (82a) 
To a suspension of NaH (12.6 mg, 0.315 mmol, 1.4 Meq.) in dry toluene (0.5 ml) under 
argon atmosphere, was added Ethyl 1,2-benzisoxazol-3-ylacetate 81 (47.2 mg, 0.23 mmol, 1.0 
Meq.) in toluene (0.5 ml) and the mixture was stirred at room temperature for 30 min. After ice 
cooling, addition of iodomethane (0.017 ml, 0.268 mmol, 1.1 Meq.) in ice-bath, the mixture 
was stirred 12 h at room temperature*5. After the reaction mixture was diluted with water and 
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extracted with AcOEt (10 ml) three times, The combined extracts were washed with brine (10 
ml), dried over MgSO4 and the solvent was removed in vacuo, The resulting residue was 
purified by column chromatography  (n-Hexane: AcOEt= 4:1) obtain a color oil 82a (32.3 mg, 
64.1%). 
Rf = 0.58 (SiO2, n-Hexane:AcOEt = 4:1); IR υmax cm-1: 1736 (C=O), 1709 
1H NMR (400 MHz, CDCl3): δ (ppm) 1.21 (3H, t, J = 7.1 Hz, CH2CH3), 1.73 (3H, d, J = 7.1 
Hz, CHCH3), 4.19 (2H, q, J = 7.1 Hz, CH2CH3), 4.27 (1H, dq, J = 7.1 Hz, CHCH3), 7.31 (1H, 
ddd, J = 14.6, 6.6, 1.5 Hz, H-5), 7.53-7.60 (2H, m, Ar-H), 7.75 (1H, dd, J =8.1, 1.0 Hz, Ar-H) 
13C NMR (100 MHz, CDCl3): δ (ppm) 14.0 (CH3), 15.7 (CH3), 38.1 (CH), 61.5 (CH2CH3), 
110.0, 120.3, 121.9, 123.4, 129.8, 157.1, 163.4 (C=N), 171.6 (C=O). 
HRFABMS: 220.0966 [M+H]+ (Caled for C12H13NO3 : 220.0974) 
  
 
Ethyl (1,2-benzisoxazol-3-yl)benzylacetate (82b) 
To a suspension of NaH (13.4 mg, 0.335 mmol, 1.4 Meq.) in dry toluene (0.5 ml) under 
argon atmosphere, was added Ethyl 1,2-benzisoxazol-3-ylacetate 81 (51.7 mg, 0.252 mmol, 1.0 
Meq.) in toluene (0.5 ml) and the mixture was stirred at room temperature for 30 min. After 
addition of benzyl bromide (0.032 ml, 0.268 mmol, 1.1 Meq.) ice cooling and the mixture was 
stirred 12 h at room temperature. After the reaction mixture was diluted with water and 
extracted with AcOEt (10×3) three times, The combined extracts were washed with brine (10 
ml), dried over MgSO4 and the solvent was removed in vacuo, The resulting residue was 
purified by column chromatography  (n-Hexane: AcOEt= 10:1) to obtain a color oil 82b (25.1 
mg, 33.7%). 
Rf = 0.34 (SiO2, n-Hexane:AcOEt = 8:1); IR υmax cm-1: 1733 (C=O) 
1H NMR (400 MHz, CDCl3): δ (ppm) 1.13 (3H, t, J = 7.1 Hz, CH2CH3), 3.38 (1H, dd, J = 13.9, 
7.1 Hz), 3.62 (1H, dd, J = 13.9, 8.4 Hz), 4.12 (2H, dq J = 7.1 Hz, CH2CH3), 4.45 (1H, dd, J = 
8.4, 7.1 Hz, CHCH3), 7.17-7.27 (5H, m, Ar-H), 7.31 (1H, ddd, J = 7.9, 6.0, 1.8 Hz, 
H-5),7.52-7.58 (2H, m, Ar-H), 7.79 (1H, d, J =8.1 Hz, H-7) 
13C NMR (100 MHz, CDCl3): δ (ppm) 13.9 (CH3), 36.5, 45.9, 61.6 (CH2CH3), 110.0, 120.4, 
122.1, 123.5, 126.8, 128.5, 128.9, 129.9, 137.7, 155.6, 163.5 (C=N), 170.5 (C=O). 
HRFABMS: 296.1281 [M+H]+ (Caled for C18H18NO3 : 296.1287) 
 
 
Bis[4-(trifluoromethyl)phenyl]methanol (86) 
To a solution 4-bromobenzotrifluoride (3.11 ml, 22.2 mmol) in THF(100 ml) at -78 oC under 
a nitrogen atmosphere was added dropwise n-BuLi (1.66 M in hexane , 18 ml, 27 mmol, 1.2 
Meq.). The mixture was stirred at -78 oC for 1 h, then 4-trifluomethylbenzaldehyde (3.94 ml, 
28.86 mmol, 1.3 Meq.) was added dropwise to the solution. The mixture was allowed to warm 
to -40 oC. After stirring for 4 h, the solution was quenched with water (40 ml), extracted with 
EtOAc (20 ml) two times. The combined extracts were washed with brine (20 ml), dried 
(MgSO4) and evaporated in vacuo. The residual oil was purified via flash column 
chromatography (SiO2, n-Hexane:AcOEt=1:4), yield 5.57 g (17.4 mmol, 78.4%) of the  
alcohol 86 as a pale yellow solid. 
Rf= 0.25 (SiO2, n-Hexane:AcOEt=6:1); IR υmax cm-1: 3351; 
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1H NMR (400 MHz, CDCl3): δ (ppm) 2.46 (1H, brs, OH), 5.93 (1H, s, CH), 7.50 (4H, d, J = 
8.2 Hz, Ar C2-H×4), 7.61 (4H, d, J = 8.2 Hz, Ar C2-H×4); EIMS m/z: 320 [M+, (76.4%)], 
301 (45.5%), 251 (91.6%), 175 (100%) 
 
 
4,4,-Bis(trifluoromethyl)benzophenone (87) 
To a solution bis[4-(trifluoromethyl)phenyl]methanol 86 (5.57 g, 17.41 mmol) in CH2Cl2 
(55 ml) under a nitrogen atmosphere was added MnO2 (15.20 g, 174.8mmol, 10 Meq.) 
portionwise at room temperature. The mixture refluxed for 1 d. After filtered with CeliteR, the 
solution was evaporated in vacuo. The residual solid was recrystallized by hexane, yield 5.43 g 
(17.07 mmol, 98.1%) of 87 as colorless needles. 
Mp 115-117 oC;Rf= 0.48 (SiO2, n-Hexane:AcOEt=6:1 ); IR υmax cm-1:1653 (C=O) 
1H NMR (400 MHz, CDCl3): δ (ppm) 7.85, 7.90 (each 4H, d, J = 8.2 Hz, C6H4x2). 
EIMS m/z: 318 [M+, (25.0%)], 299 (9.6%), 173 (100.0%), 145 (65.6%), 59 (43.8%) 
 
 
4,4,-Bis(trifluoromethyl)benzophenone Oxime (88) 
After pyridine (1 ml) was added to a vessel with 4,4,-bis(trifluoromethyl)- 
benzophenone 87  (136.0 mg, 0.427mmol) and hydroxylammonium chloride (56.8 mg, 
0.817 mmol, 1.9 Meq.), the solution was heated to reflux for 1h, the solvent was removed in 
vacuo and water (2 ml) was added. The mixture was extracted twice with ethyl acetate (2 ml), 
and the combined extracts were washed successively with 1ml HCl (0.05M), water (2 ml), sat. 
NaHCO3 (2 ml), and brine (2 ml), after dried with MgSO4 the solvent was evaporated in vacuo. 
The residual solid was recrystallized from hexane gave 4,4,-bis(trifluoromethyl)benzophenone 
oxime 88 (115.3 mg, 0.346 mmol, 81.0%) as a colorless neddles. 
Mp 162-164 oC;Rf = 0.50 (SiO2, n-Hexane:AcOEt=4:1 ); IR υmax cm-1: 3281 
1H NMR (400 MHz, CDCl3): δ (ppm) 7.53 (2H, d, J = 8.3 Hz, ArH), 7.56, 7.62 (each 2H, d, J 
= 8.3 Hz, ArH), 7.76 (2H, d, J = 8.3 Hz), 8.59 (1H, brs, OH); EIMS m/z: 333 [M+, (72.4%)], 
316 (62.2%), 296 (25.9%), 248 (44.3%), 172 (49.2%), 162 (26.1%), 145 (100%) 
 
 
4,4,-Bis(trifluoromethyl)benzophenone O-p-Tolylsulfonyloxime (89) 
To an ice-cold solution of 4,4,-bis(trifluoromethyl)benzophenone oxime 88 (4.27g, 
12.81mmol) and Et3N (2.14ml, 15.37mmol, 1.2Meq.) in dichloromethane (30ml) was slowly 
added a solution of p-TsCl (2.98g, 15.64mmol, 1.2Meq.) in dichloromethane (10ml), and this 
mixture was stirred at room temperature for 4 h. After the reaction was quenched with water 
(20ml), the mixture was extracted twice with dichloromethane (20ml). The combined extracts 
were washed with sat. NaHCO3 (20ml), and the dichloromethane solution was dried over 
MgSO4. The dichloromethane was removed in vacuo, and recrystallization of the residual solid 
from ethyl acetate-hexane gave a colorless needle 89 (5.09g, 10.44mmol, 81.5%). 
Mp 162-165 oC; Rf = 0.55 (SiO2, n-Hexane:AcOEt =4:1); IR υmax cm-1: 3447, 1385, 1321. 
1H NMR (400 MHz, CDCl3): δ (ppm) 2.48 (3H, brs, CH3), 7.40 (4H, dd, J = 8.2, 2.8 Hz, ArH), 
7.50 (2H, d, J = 8.8 Hz, ArH), 7.62 (2H, d, J = 8.2 Hz, ArH), 7.75 (2H, d, J = 8.2 Hz, ArH), 
7.91 (2H, d, J = 8.2 Hz, ArH). 
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FABMS m/z: 488[M+H+] 
 
 
Ethyl 2-Benzyl-3-methoxyliminopropionate (101) 
Ethyl 3-oxo-3-phenylpropionate 75 (0.9 ml, 5.20 mmol, 1.0 Meq.) was added to a stirred 
solution of pyridne (10 ml) containing O-methylhydroxylamine hydrochloride (502.9 mg, 5.72 
mmol, 1.1 Meq.) under Ar. After stirred 1 d at room temperature, the reaction mixture was 
diluted with water (10 ml) and extracted three times with AcOEt (20 mlx3). The combined 
organic layers were washed with brine (10 ml) and dried over MgSO4. Concentration in vacuo 
yielded crude residue, which were purified by column chromatography (SiO2, n-Hexane: 
AcOEt= 10:1) gave 101 as a colorless oil (1.02 g, 88.7%). 
Rf = 0.63 (SiO2, n-Hexane:AcOEt=5:1 ); IR υmax cm-1: 1737(C=O)  
1H NMR (400 MHz, CDCl3): δ (ppm) 1.21 (3H, t, J = 7.1 Hz, CH2CH3), 3.75 (2H, s, CH2), 
4.00 (3H, s, OCH3), 4.16 (2H, q, J = 7.1 Hz, CH2CH3), 7.36-7.38 (3H, m, Ar-H), 7.62-7.65 (2H, 
m, Ar-H); EIMS m/z: 221 [M+, (15.0%)], 220[(M-1)+, 99%], 175 (23.2%), 143 (10.9%), 133 
(24.6%), 117 (43.0%) 
 
 
Ethyl 2-(methoxyiminophenylmethyl)-5-oxo-hexanoate (103) 
To a stirred solution of ethyl 3-phenyl-3-methoxyliminopropionate 101 (100.2 mg, 0.452 
mmol, 1.0 Meq.) in dry THF (0.6 ml) under Ar, was added TMG (0.011 ml, 0.090 mmol, 0.2 
Meq.) in THF (0.4 ml). After stirred 30 min, methyl vinyl ketone (MVK, 0.14 ml, 1.67 mmol, 
3.7 Meq.) was added dropwise. The reaction solution was stirred 7 days at room temperature. 
The mixtrue was diluted with sat. NH4Cl (5 ml), then extracted three times with AcOEt (5 ml), 
the combined organic layers were washed with brine (10 ml), dried over MgSO4 and 
concentrated in vacuo to give a residue oil, which were purified by column chromatography 
(SiO2, n-Hexane: AcOEt= 8:1->4:1->2:1) to give 103 as a colorless oil (54.9 mg, 41.7%) and 
recovered 101 (32.1 mg, 32.1%). 
Rf = 0.21 (SiO2, n-Hexane:AcOEt=5:1 ); IR υmax cm-1: 1734 (C=O), 1715 (C=O). 
1H NMR (400 MHz, CDCl3): δ (ppm) 1.15 (3H, t, J = 7.2 Hz, CH2CH3), 1.98-2.07 (1H, m, 
H-3), 2.03 (3H, s, CH3), 2.37-2.48 (1H, ddd, J=14,6, 14.2, 7.3 Hz, H-3), 2.51-2.60 (2H, m), 
3.95 (3H, s, NOCH3), 4.02 (1H, dd, J = 10.6, 7.3, H-2), 4.07-4.18 (each 1H, dq, J= 7.1 Hz, 
CH2CH3), 7.36-7.38 (3H, m, Ar-H), 7.59-7.62 (2H, m). 
13C NMR (100 MHz, CDCl3): δ (ppm) 13.9 (CH2CH3), 22.1, 29.7, 40.9, 43.6, 60.8, 62.0, 126.6, 
128.5, 129.3, 135.0, 155.5 (C=N), 171.4 (C=O), 207.9 (C=O). 
HRFABMS:314.1362 [M+Na]+ (Caled for C16H21NaNO4 : 314.1368) 
 
 
N-Methoxy-N-methylnicotinamide (116) 
Diisopropylethylamine (21.5ml, 126.45mmol, 4.5Meq.) was added dropwise to a solution of 
nicotinoyl chloride (5.00g, 28.09mmol) and N,O-dimethylhydroxylamine hydrochloride (3.83g, 
39.24mmol, 1.4Meq.) in anhydrous methylene chloride (50ml) at 0oC under Ar. The resulting 
mixture slowly warmed to room temperature. After stirred for 12h, the reaction mixture was 
then diluted with methylene chloride (30 ml) and washed successively with water (40ml) and 
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brine (40ml). The aqueous layer was diluted with aqueous sodium bicarbonate solution (50 ml) 
and then extracted with methylene chloride (50ml×2). The combined organic layers were 
dired over MgSO4, filtered and concentrated under reduced pressure. The resulting residue was 
purified by column chromatography obtain a yellow oil 116 (4.06g, 87.0%). 
Rf= 0.35 (SiO2, CH2Cl2: MeOH=5:1); IR υmax cm-1: 1635 (C=O); 
1H NMR (400 MHz, CDCl3): δ (ppm) 3.40 (3H, brs, NCH3), 3.56 (3H, s, OCH3), 7.37 (1H, 
ddd, J = 7.2, 4.9, 1.6 Hz, H-5), 8.03 (1H, dt, J = 7.9, 1.6 Hz, H-4), 8.69 (1H, dd, J = 4.9, 1.0 Hz, 
H-6), 8.96 (1H, d, J = 1.6 Hz, H-2). 
 
 
1-(Pyridin-3-yl)prop-2-en-1-ol (117).  
A solution of vinyl magnesium bromide (74 ml, 74 mmol, 2.0 Meq.) in THF was added 
dropwise into another solution of 3-pyridinecarbaldehyde (2.64 ml, 37 mmol, 1.0 Meq.) in 
THF (160 ml) at 0 oC and the resulting mixture was allowed to stirred at the same temperature 
for 30 minutes and another 3 hours at room temperature. After the reaction was finished, sat. 
NH4Cl (40 ml) was used to quench the reaction. The mixture was filtered and the filtrate was 
then concentrated where ethyl acetate (3 x 40 ml) was used to extract the aqueous layer. The 
combined extracts were washed with brine (50 ml), dried (MgSO4) and evaporated in vacuo. 
The residual oil was purified via flash column chromatography (n-Hexane:AcOEt=1:4), yield 
3.72 g (98.2 %) 1-(pyridin-3-yl)prop-2-en-1-ol (117) as a yellow oil.  
IR υmax cm-1: 1642, 1581, 1479;.  
1H NMR (400 MHz, CDCl3): δ (ppm) 5.22-5.24 (1H, m), 5.25 (1H, d, J = 1.2 Hz), 5.37 (1H, 
ddd, J = 17.4, 2.6, 1.2 Hz),  6.03 (1H, ddd, J = 10.6, 5.6, 1.2 Hz), 7.27-7.30 (1H, m), 7.74 (1H, 
dt, J = 7.8, 1.6 Hz), 8.44 (1H, td, J = 4.6, 1.6 Hz), 8.52 (1H, t, J = 2.4 Hz) ;  
13C NMR (100 MHz, CDCl3): δ (ppm) 72.2, 115.4, 123.4, 134.5, 138.9, 139.7, 147.3, 147.6. 
HRFABMS: 136.0756 [M+H]+ (Caled for C8H10NO : 136.0762) 
 
 
(2R)-2-(3-Pyridinyl)-5-buthoxycarbonyl-1-pyrroline (112):  
Method A: To a solution of 1-(pyridin-3-yl)prop-2-en-1-ol (117) (95.2 mg, 0.704 mmol, 1.0 
Meq. ) in DMSO (2 ml) under Ar was added IBX (300.9 mg, 1.075 mmol, 1.5 Meq.) and the 
suspension was stirred 6 h at room temperature. After diluted with water (8 ml), the solution 
was filtered and the filtrate was extracted by CH2Cl2 (15 ml) three times, then the organic layer 
was washed with water (5 ml) for four times and washed with brine, dried over MgSO4, and 
concentrated in vacuo to afford crude 114 (91.8 mg, 0.689 mmol, 97.9%). the crude was used 
in next reaction rapidly. 
Method B: To a solution of 1-(pyridin-3-yl)prop-2-en-1-ol (117) (500.9 mg, 3.71 mmol, 2.0 
Meq. ) in CH2Cl2 ( 5 ml) under Ar was added MnO2 (3.206 g, 36.9 mmol, 20.0 Meq. ) and the 
black suspension was refluxed for 1 day, then cold to room temperature. The reaction mixture 
was filtered over Celite and concentrated in vacuo to afford crude 114 (476.1 mg, 3.58 mmol, 
96.5%). the crude was rapidly used in next reaction. 
A solution of imine 115 (546.4 mg, 1.850 mmol, 1.0 Meq.) and guanidine (+)-ChibaG 11a 
(74.1 mg, 0.185 mmol, 0.1 Meq.) in THF (2.5 ml) at -40 oC under a argon atomoshere was 
added drowise crude 114 in THF (5 ml). The mixture was stirred at -40 oC for 30 min, and then 
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allowed to warm to -15 oC. After stirred for 1 week, the solution was evaporated in vacuo. The 
residual oil was divided into two fractions by NH-silica (n-Hexane: AcOEt = 5:1 and AcOEt), 
gave recoved imine 115 (115.4 mg, 21.1%) and crude 113 (828.4 mg, 1.93 mmol 104.5%), this 
crude was directly subjected to the next step. 
Crude 113 was dissolved in THF (2.5 ml), 15% citric acid (5 ml) was added dropwise. The 
mixture was stirred for 12h at room temperature. When the reaction was finished, the solution 
was cooled to 0 oC and Sat. NaHCO3 aq. was added dropwise up to pH>8. The mixture was 
extracted with AcOEt (20 ml) three times. The organic layer was washed with brine (10 ml), 
dried over MgSO4, and concentrated. Flash chromatography (n-Hexane: AcOEt: Et3N = 
50:50:5) gave pyrroline 112 (334.9 mg, 1.36 mmol, 73.4% from 115, 94% ee). 
IR υmax cm-1: 1729 (C=O), 1617 (C=N).  
1H NMR (400 MHz, CDCl3): δ (ppm) 1.51 (9H, brs), 2.15-2.24 (1H, m), 2.32-2.42 (1H, m), 
2.95-3.04 (1H, m), 3.11-3.20 (1H, m), 4.84 (1H, t, J = 6.6 Hz), 7.37 (1H, dd, J = 7.9, 4.8 Hz), 
8.27 (1H, dd, J = 7.9, 1.6 Hz), 8.68 (1H, d, J = 4.8 Hz), 9.01 (1H, s). 
13C NMR (100 MHz, CDCl3): δ (ppm) 26.6, 28.0, 35.1, 75.3, 81.4, 123.4, 129.6, 135.1, 149.2, 
151.6, 171.9, 173.6. [α]D21.7=-90.96 (c 0.5, CH2Cl2). 
HRFABMS: 247.1440 [M+H]+ (Calcd for C14H18N2O2: 247.1447). 
 
 
(2S,5S)-5-(3-Pyridyl)proline tert-butyl ester (118): 
To a solution of pyrroline 112 (299.7 mg, 1.22 mmol) in i-PrOH (9 ml), 10% Pd/C (30 mg, 
10 w%) was added. The black suspension was stirred under argon atmosphere (1 atm) for 1 d at 
room temperature. The reaction mixture was filtered through a pad of Celite and concentrated 
in vacuo to afford a oil residue. After purified by chromatography (SiO2, 5% Et3N in AcOEt), 
proline ester 118 was obtained as a yellow oil (284.0 mg, 94.0%). 
IR υmax cm-1: 3364 (N-H), 1725 (C=O).  
1H NMR (400 MHz, CDCl3): δ (ppm) 1.50 (9H, brs), 1.66-1.73 (1H, m), 2.06-2.13 (1H, m), 
2.16-2.26 (2H, m), 3.85 (1H, dd, J = 9.2, 4.8 Hz), 4.24 (1H, dd, J = 9.2, 6.0 Hz), 7.27-7.30 (1H, 
m), 7.88 (1H, d, J = 7.8 Hz), 8.50 (1H, d, J = 4.6 Hz), 8.62 (1H, s).  
13C NMR (100 MHz, CDCl3): δ (ppm) 28.0, 30.7, 34.1, 60.6, 60.9, 81.3, 123.5, 134.3, 138.9, 
148.6, 148.7, 174.3. [α]D19.5=-36.5 (c 0.5, CH2Cl2).  
HRFABMS: 249.1603 [M+H]+ (Caled for C14H21N2O2 : 249.1603) 
 
 
(2S,5S)-2-Carboxynornicotine (119) 
To a solution of 118 (147.3 mg, 0.593 mmol) in CH2Cl2 (2 ml) under Ar, TFA (2 ml ) was 
added dropwise at 0oC. The suspension was stirred for 1 d at room temperature. The reaction 
mixture was evaporated in vacuo, after diluted with distilled water (8 ml ), the water layer was 
washed with Et2O (8 ml) 3 times, Aqueous fractions were concentrated in vacuo, and the 
residue was then freeze dried to afford a crude solid, which was recrystallized by MeCN, 
obtained 119 as a pale yellow solid (115.1 mg, 67.1%).  
Mp: 193-195 oC. IR υmax cm-1: 3394 (N-H), 1668 (C=O).  
1H NMR (400 MHz, D2O): δ (ppm) 2.06-2.16 (1H, m), 2.35-2.41 (2H, m), 2.44-2.50 (1H, m), 
4.28-4.31 (1H, m), 4.88-4.93 (1H, m), 8.00-8.03 (1H, m), 8.60-8.64 (1H, m), 8.73-8.74 (1H, 
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m),  8.87 (1H, s).  
13C NMR (100 MHz, D2O): δ (ppm) 29.9, 31.1, 61.1, 62.8, 128.2, 135.3, 142.5, 143.5, 146.3, 
174.5.  
HRFABMS: 193.0980 [M+H]+ (Caled for C10H13N2O2 : 193.0972) 
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